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Amanda R. Stram  
 
MITOCHONDRIAL PROTEIN ACETYLATION AND LEFT VENTRICULAR FUNCTION IN 
A MODEL OF HYPERTROPHIC CARDIOMYOPATHY AND HEART FAILURE 
 
Rationale: The childhood heart disease of Friedreich’s Ataxia (FRDA) is characterized by 
hypertrophy and failure. It is caused by loss of frataxin (FXN), a mitochondrial protein involved 
in energy homeostasis. FRDA model hearts have increased mitochondrial protein acetylation and 
impaired sirtuin 3 (SIRT3) deacetylase activity. Protein acetylation is an important regulator of 
cardiac metabolism and SIRT3 is protective in heart disease. The underlying pathophysiology of 
heart failure in FRDA is unclear. I suspect that increased acetylation in FRDA heart mitochondria 
damages cardiac energy homeostasis by inhibiting activity of key enzymes involved in heart 
metabolism.  
 
Objective: My project tested the hypothesis that altered acetylation of mitochondrial proteins 
contributes to the cardiomyopathy of FRDA. 
 
Methods: Conditional mouse models of FRDA cardiomyopathy with ablation of FXN (FXN KO) 
or FXN and SIRT3 (FXN/SIRT3 DKO) in the heart were compared to healthy controls. Hearts 
were evaluated using echocardiography, cardiac catheterization, histology, protein acetylation and 
expression. FXN KO mice were treated with NAD+ replacement therapy with nicotinamide 
riboside (NR), and FXN/SIRT3 DKO mice were treated with FXN protein replacement therapy.  
 
Results: Acetylation was temporally progressive and paralleled evolution of heart failure in the 
FXN KO model. High levels of acetylation were associated with cardiac fibrosis, mitochondrial 
damage, impaired fat metabolism, and diastolic and systolic dysfunction. Acetylation correlated 
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strongly with worse heart function, and loss of SIRT3 in the FXN KO mouse resulted in 
significant decrease in ejection fraction and fractional shortening. Treatment of the FXN/SIRT3 
DKO with FXN protein therapy reduced acetylation but was not sufficient to fully rescue heart 
function. Increasing NAD+ with NR-treatment in the FXN KO lead to increased mitochondrial 
protein acetylation and did not improve cardiac outcome. 
 
Conclusion: I found a strong negative correlation between heart function and mitochondrial 
protein acetylation. My findings also provide evidence that absence of SIRT3 expression in the 
FXN KO heart exacerbates features of heart failure, and that SIRT3 expression is necessary to 
rescue the FXN KO heart. These results suggest that SIRT3 inactivation and abnormal acetylation 
contribute to the pathophysiology of heart disease in FRDA.  
 
 
R. Mark Payne, MD, Chair 
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CHAPTER 1 
 
ACETYLATION AS A POSTTRANSLATIONAL MODIFICATION OF LYSINE RESIDUES 
ON MITOCHONDRIAL PROTEINS AND ITS IMPLICATION IN THE HEART DISEASE OF 
FRIEDREICH’S ATAXIA 
 
Introduction 
  
 Heart failure carries a significant morbidity and mortality disease and cost burden in the 
United States (1). The underlying pathogenesis and molecular mechanism underlying heart failure 
is not well understood. Treatment modalities for heart failure consist of reducing symptoms and 
hospitalizations, yet it remains a progressive and frequently fatal disease (2). This highlights the 
importance of supporting scientific investigations that will illuminate the mechanisms responsible 
for heart failure. 
 Mounting evidence suggests that mitochondrial dysfunction is an important pathogenic 
mechanism for heart disease progression, such as that arising from hypertension, ischemia, and 
hypertrophic cardiomyopathy (3, 4). Mitochondrial protein acetylation is emerging as a critical 
post-transcriptional modification that acts to maintain normal mitochondrial function and heart 
metabolism (5). Sirtuin 3 (SIRT3) is a NAD+-dependent deacetylase that responds to intracellular 
metabolic cues and is activated in response to increased levels of NAD+. It is the only known 
protein responsible for mitochondrial deacetylation in the heart. Its targets include enzymes 
important to energy homeostasis, such as long chain acyl CoA (LCAD), pyruvate dehydrogenase 
(PDH), acetyl CoA synthetase 2 (AceCS2), and ATP synthase, among others (6).  
 Friedreich’s Ataxia (FRDA) is a congenital mitochondrial disorder resulting in 
multisystem failure and early mortality in those afflicted (7, 8). The cardiac manifestation of 
FRDA results in hypertrophic cardiomyopathy progressing to heart failure. The heart disease of 
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FRDA appears to mimic the cellular, metabolic and physiologic adverse remodeling leading to 
heart failure that is common in other heart diseases. Specifically, left ventricle hypertrophy and a 
switch from oxidative metabolism to glycolysis are features of FRDA heart disease as well as 
prominent characteristics of evolving heart failure. FRDA heart failure is relentlessly progressive 
and there is no cure.  
 There is evidence that mitochondrial protein acetylation is deregulated in hearts of a 
murine model FRDA cardiomyopathy (9). This deregulation of acetylation arises from SIRT3 
inhibition and results in hyperacetylation of protein lysine residues and mitochondrial 
dysfunction. Because SIRT3 is involved in key components of heart metabolism and 
mitochondrial integrity, it is likely that SIRT3 dysfunction and mitochondrial protein 
hyperacetylation play a key role in the cardiomyopathy of FRDA. Presented here is a summary of 
the emerging data on mitochondrial protein lysine acetylation and a discussion on the implication 
of abnormal acetylation in the childhood heart disease of FRDA.  
 
 
 
SIRT3 and lysine acetylation in mitochondria 
 
  
 Sirtuins are a family of NAD+-dependent enzymes that regulate diverse biological 
functions. There are seven identified sirtuins, sirtuin 1-7, with three located in mitochondria, 
sirtuin 3-5. Sirtuin 3 (SIRT3) is a deacetylase that responds to cellular energy status and utilizes 
an “acetylation switch” to modify protein function (10-12).  SIRT3 uses NAD+ as a cofactor to 
catalyze the removal of acetyl groups from lysine side chains. Mitochondria appear to utilize 
lysine acetylation-deacetylation of proteins to respond quickly to metabolic cues and thus, 
acetylation represents an important post translational mechanism for maintaining normal 
mitochondrial function and metabolism (12).  
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 While early reports suggested the presence of an acetyltransferase mechanism (13), 
definitive identification of such a counter enzyme has not been successful. Rather, acetylation 
appears to be non-enzymatic, and related to acetyl CoA availability and reactivity in the 
mitochondrial matrix (14, 15).  
 In general, SIRT3 protein targets are activated in response to removal of acetyl groups. 
Many SIRT3 targets are important to energy generation and utilization, such as long-chain acyl-
CoA dehydrogenase (LCAD) (16, 17), pyruvate dehydrogenase (PDH) (18), acetyl-CoA 
synthetase 2 (AceCS2) (19), Isocitrate dehydrogenase 2 (IDH2) (20), and ETC complexes I-III 
and CV (ATP synthase)(21-24), among others important to core metabolic processes (6, 25-27) 
(Figure 1-1). SIRT3 deacetylation has been shown to increase the activity of energy-generating 
Figure 1-1. Reversible Lysine Acetylation. Mitochondrial protein lysine acetylation is regulated by 
the NAD+-dependent deacetylase, SIRT3. SIRT3 responds to mitochondrial energy and redox state to 
target proteins that, in turn, signal changes in cellular function. Ac-CoA = Acetyl-CoA; FAO = fatty 
acid oxidation; ? = no identified acetyltransferase enzyme; Ac-K = acetyl-lysine; K = lysine; NAM = 
nicotinamide; ADPR = ADP-Ribose; ROS = reactive oxygen species; mPTP = mitochondrial 
permeability transition pore. 	
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enzymes in the electron transport chain. SIRT3 deacetylation activates CI-NDUFA9, CII-SDHA 
and ATP synthase (21, 22, 28, 29), thus SIRT3 acts directly to increase energy currency in the 
form of ATP and NAD+ in cells. Fatty acid metabolism, a major source of energy for the heart, is 
regulated by SIRT3 deacetylation of several enzymes including AceCS2, which stimulates 
conversion of acetate into acetyl CoA (19, 30), 3-hydroxy-3-methylglutaryl-CoA synthase 2 
(HMGCS2) stimulating ketogenesis (31), and LCAD, stimulating fatty acid oxidation (17). 
Carbohydrate metabolism is regulated by deacetylation of cyclophilin D, releasing hexokinase 2 
and causing a decrease in glycolysis (32), and PDH, which activates in response to deacetylation 
by SIRT3 (33). 
 SIRT3 also targets proteins that maintain physiologic redox balance and provide 
protection from oxidative damage. Deacetylation of superoxide dismutase 2 (SOD2) increases its 
activity as a free radical scavenger (34-36). IDH2 responds to deacetylation with increased 
metabolic activity in the TCA cycle, and is also associated with protection from oxidative stress-
related cell death (20). Mitochondrial permeability transition pore-mediated apoptosis is also 
regulated by deacetylation, with deacetylation by SIRT3 inhibiting pore opening (25). 
Mitochondrial OGG1 (8-Oxoguanine glycosylase) stabilizes in response to deacetylation by 
SIRT3 under oxidative stress and protects from intrinsic apoptosis (37).  
 There is particular functional relevance of acetylation as a post-translational modification 
in cardiovascular disease. Given the heart’s reliance on functional mitochondrial metabolism due 
to its constant demand for energy substrates, it is not surprising that SIRT3 is emerging as an 
important player in cardiovascular disease (38). For example, SIRT3 has been shown to protect 
against oxidative stress (39-41), attenuate fatty acid accumulation in the heart (42) and prevent 
development of stress-induced cardiac hypertrophy (43). Mice with ablation of SIRT3 have 
mitochondrial dysfunction resulting in myocardial energy loss, develop cardiac hypertrophy and 
fibrosis in response to mechanical stress (44), and are more susceptible to the detrimental effects 
of ischemia/reperfusion injury (45).  
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Friedreich’s Ataxia hypertrophic cardiomyopathy and heart failure 
  
 The etiology of Friedreich’s Ataxia (FRDA) arises from a homozygous GAA triplet 
expansion in the FXN gene (Frda) resulting in dysfunctional transcription and decreased 
expression of the FXN protein (46). Prevalence of FRDA is estimated at 1:29,000 -1:50,000, with 
a carrier frequency of 1:60-1:110 (8). FRDA manifests clinically as a multi-systemic disease with 
progressive neuronal degeneration, hypertrophic cardiomyopathy and endocrine disturbances, 
such as diabetes mellitus (46). Clinical symptom onset typically occurs in the second decade of 
life, with a mean age of death in the third or fourth decades (8, 47). Cardiac dysfunction is the 
most common overall cause of death and causes premature death in 60-80% of FRDA patients 
(48, 49). The detectable cardiac phenotype of FRDA results in abnormal electrocardiogram 
changes, arrhythmias, and left ventricular hypertrophy with severe interstitial fibrosis progressing 
to heart failure (50). 
 FXN is a highly conserved mitochondrial protein that functions in energy metabolism by 
acting as an iron binding protein in iron-sulfur enzyme biosynthesis, thus affecting multiple 
enzyme systems such as respiratory chain complexes I, II, and III, and aconitase of the TCA cycle 
(50-52). Diminished FXN expression results in mitochondrial dysfunction, impaired energy 
generation, decreased mitochondrial NAD+/NADH ratios, and increased oxidative stress with a 
shift in the redox state (53). Under normal conditions, FXN expression is most robust in tissues 
enriched in mitochondria and with high metabolic demand, such as heart, liver, skeletal muscle, 
kidney and brown adipose tissue (46). In fact, FXN expression is highest in healthy heart tissue 
(54). FRDA patients have decreased myocardial levels of ATP, even in the absence of detectable 
contractile dysfunction, which underscores the importance of FXN in meeting energy needs. 
FXN-deficient cardiomyocytes show increased mitochondrial density, likely as a proliferative 
compensatory mechanism in response to inherent mitochondrial dysfunction (55).  
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 The pathophysiology of FRDA cardiomyopathy remains under investigation, although it 
can be reasonably postulated that failing mitochondrial energetics contribute to clinical 
characteristics. There is no cure for FRDA and no methods are available to slow disease 
progression. Antioxidants and iron chelation have been investigated as therapeutic candidates, yet 
none have shown evidence of efficacy in clinical settings (56). Replacing FXN using viral gene 
therapy and targeted protein replacement show promise in animal studies. We are still far from 
understanding the exact function of FXN and the biochemical events leading to the 
pathophysiology of the cardiomyopathy of FRDA.  
 
  
Deregulation of Mitochondrial Protein Lysine Acetylation in Friedreich’s Ataxia Heart 
Failure 
  
 SIRT3 is inhibited in FXN-deficient heart mitochondria, causing global hyperacetylation 
of protein lysine residues as well as increased acetylation of specific targets of SIRT3, including 
LCAD and AceCS2 (9). Failure of SIRT3 to deacetylate important metabolic enzymes in 
response to existing energy needs will result in a paucity of metabolic substrates and, in turn, lead 
to mitochondrial metabolic dysfunction and presumably worsen the function of failing FXN-
deficient mitochondria. The ratio of NAD+/NADH is low in the FXN-deficient heart (9), likely 
because of dysfunctional mitochondrial oxidative metabolism that fails to oxidize NAD+ from the 
available mitochondrial pool. Because SIRT3 deacetylase activity relies on the bioavailability of 
its required cosubstrate NAD+, the relative deficiency of NAD+ is likely the key mechanism 
behind SIRT3 inhibition in FRDA hearts. 
 NAD+ is a vital component of mitochondrial and cellular homeostasis, participating in 
oxidoreduction reactions for energy generation, as a cofactor for diverse enzymatic processes, and 
evens acts as a signaling molecule. While the precise mechanisms that act to regulate NAD+ in 
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the cell are still being explored, it is known that NAD+ can be regenerated via recycling of 
precursors of the vitamin B3 family, namely, nicotinic acid (Na), nicotinamide (Nam) and 
nicotinamide riboside (NR). In the mouse heart, the vast majority of NAD+ synthesized from 
precursors comes from Nam and NR, which are converted into nicotinamide mononucleotide 
(NMN) prior to entry into the mitochondria (57). Recent work in animal models has shown that 
exogenous treatment with either NR or NMN can boost NAD+ levels in mitochondria and activate 
sirtuins (58-61). NAD+ replacement therapy has garnered special attention in recent years as an 
attractive therapeutic potential for pharmacological modulation of protein lysine acetylation to 
improve cardiac metabolism and physiologic function. In the FXN-deficient heart, recovering 
diminished NAD+ levels could alleviate inhibition of SIRT3 to reinstate its diverse protective 
effects on the heart. In fact, reversal of hyperacetylation in FXN-deficient cells can be achieved 
by replacing NAD+ together with SIRT3 in vitro (9). It remains to be shown whether such 
supplementation is similarly efficacious in such cells in vivo, and would be of great interest to 
pursue. 
 
 
Conclusion 
  
 The rapid and recent increase in knowledge of protein acetylation as a post-translational 
processing mechanism with metabolically-enriched mitochondrial targets has lead to a 
tremendous amount of new information on the mitochondrial orchestration of cellular energy and 
metabolism. The functional significance of many of these post-translational modifications in the 
mitochondria, in regard to their impact in the pathophysiology of disease, has not been fully 
explored and needs to be delineated further. However, it is evident that protein signaling via 
reversible protein modifications is widely and extensively used in mitochondria as a mechanism 
to respond to shifts in nutrient and redox status. Given the fundamental role of mitochondria in 
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providing energy and regulating metabolic homeostasis of the cell, and especially in the heart, 
and the close link between mitochondrial dysfunction and disease, ongoing investigations will 
likely continue to yield clues to functional significance. Mitochondrial protein modifications 
show promise for use as modifiable mitochondrial targets for therapies aimed to regulate cardiac 
metabolism in an attempt to alleviate the burden of heart disease.   
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CHAPTER 2 1	
 2	
PROGRESSIVE MITOCHONDRIAL PROTEIN LYSINE ACETYLATION AND HEART 3	
FAILURE IN A MODEL OF FRIEDREICH’S ATAXIA CARDIOMYOPATHY (62)	 4		 5	
Introduction 6	
  7	
 Heart disease and heart failure exert a significant morbidity and mortality burden 8	
worldwide. Abnormal metabolism and metabolic remodeling are common pathologic features in 9	
heart disease, such as in obesity and diabetes-related cardiomyopathy (63, 64), ischemia (65), and 10	
heart failure (4, 66). Mitochondrial dysfunction and heart disease are closely linked (67), and 11	
because mitochondria are central to regulating cellular energy and fulfilling the high demands of 12	
cardiac metabolism, it is expected that mitochondrial dysfunction plays a key pathologic role in 13	
abnormal cardiac metabolism (68).  14	
 Mitochondrial protein acetylation is an important post-translational regulatory 15	
mechanism of heart metabolism that has emerged in recent years. Acetylation in mitochondria is 16	
controlled by the NAD+-dependent deacetylase, sirtuin 3 (SIRT3). SIRT3 responds to cellular 17	
energy status and utilizes an “acetylation switch” to modify protein function (11) in order to 18	
respond quickly to metabolic cues and thus, operates a chief mechanism for maintaining normal 19	
mitochondrial function and metabolism (12). SIRT3 targets enzymes that are typically activated 20	
in response to removal of acetyl groups, and which are important to energy generation and 21	
utilization, such as very-long-chain, long-chain, and medium-chain acyl-CoA dehydrogenases 22	
(VLCAD, LCAD and MCAD) (16, 69), pyruvate dehydrogenase (PDH) (18), acetyl CoA 23	
synthetase 2 (AceCS2) (19), and electron transport chain (ETC) complexes I-III (22, 24, 70). 24	
Additionally, SIRT3 appears to deacetylate other important proteins, such as those that provide 25	
protection from oxidative damage, e.g., superoxide dismutase 2 (SOD2) (34). It is worth noting 26	
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here that enzyme response to acetylation state is an area of continuing investigation. For instance, 27	
others have reported an increase in activity in LCAD in response to acetylation, specifically in 28	
obesity-related heart disease (71).  29	
 Beneficial effects of SIRT3 activity in the heart are well documented. For example, 30	
SIRT3 has been shown to protect against oxidative stress, attenuate fatty acid accumulation in the 31	
heart (42), and prevent development of stress-induced cardiac hypertrophy (72). Mice lacking 32	
SIRT3 have mitochondrial dysfunction eventually resulting in myocardial energy loss, develop 33	
hypertrophy and fibrosis in response to mechanical stress (44), and are more susceptible to the 34	
detrimental effects of ischemia/reperfusion injury (45). 35	
 Acetylation is most exciting in the context of heart disease in that it has potential as a 36	
therapeutically modifiable target. For example, recent work has shown that exogenous treatment 37	
with NAD+ precursors can increase NAD+ levels in mitochondria, activate sirtuins to reduce 38	
protein acetylation, and improve cardiac outcome (58, 59). 39	
 The heart disease of Friedreich’s Ataxia (FRDA) results from inherited deficiency of 40	
frataxin (FXN), a mitochondrial protein important in energy homeostasis. FXN is a highly 41	
conserved mitochondrial matrix protein that functions in iron-sulfur cluster assembly, which is 42	
integral to mitochondrial metabolic machinery (73). Reduced expression of FXN in FRDA results 43	
in impaired energy generation, a decreased NAD+/NADH ratio, and increased oxidative stress 44	
(74-76). In addition to ataxia, patients often develop hypertrophic cardiomyopathy and heart 45	
failure. The vast majority of patients who go on to develop cardiomyopathy are asymptomatic 46	
until late stages of disease. The most frequent cause of mortality in FRDA arises from cardiac 47	
etiology, most commonly due to congestive heart failure (48). There is no known cure.  48	
 Mice with conditional loss of FXN in the heart develop cardiac hypertrophy as early as 5 49	
weeks of age, followed by transition to dilated cardiomyopathy and heart failure by 50	
approximately 8 weeks of age (77). Certain biochemical and structural changes occur in the 51	
FRDA mouse model heart as early as 4 weeks of age, including reduced activity of important 52	
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metabolic enzymes (such as those of the ETC complexes and aconitase) and mitochondrial 53	
ultrastructure abnormalities (77). The importance of these findings is that underlying changes in 54	
the FRDA heart originate prior to overt abnormalities in cardiac function and thus, may present a 55	
window of opportunity for intervention before irreversible changes occur.  56	
 We previously reported that mitochondrial proteins in FRDA mouse model hearts have 57	
increased acetylation and decreased SIRT3 activity, resulting in increased acetylation of several 58	
important metabolic enzymes, including LCAD, MCAD, AceCS2, and the ETC (76, 78). The 59	
reduction in SIRT3 activity is likely due to insufficient NAD+ bioavailability as a result of 60	
dysfunctional energy metabolism, and possibly by direct oxidative modification of the native 61	
protein. The impact of abnormal acetylation in the FRDA heart has not been investigated. 62	
Because of the important role that acetylation plays in cardiac function, we believe that loss of 63	
SIRT3 and resultant mitochondrial protein hyper-acetylation contributes to the heart disease of 64	
FRDA.  65	
 The purpose of the present study was to document the changes in physiology and 66	
function that evolve over time in a model of FRDA heart failure using both non-invasive (ECHO) 67	
and invasive left heart catheterization, and match the trajectory of cardiac pathophysiology to the 68	
protein acetylation profile along the course of disease in order to determine the link between 69	
acetylation of mitochondrial proteins and FRDA heart disease.   70	
 71	
 72	
Results 73	
 74	
Cardiac hypertrophy and diastolic dysfunction are early and persistent findings in FXN KO hearts  75	
  76	
 We used an established conditional mouse model of FRDA heart failure with absence of 77	
FXN in the heart (FXN MCK-Cre KO, referred to here as “FXN KO”) compared to healthy 78	
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littermates (FXNfl/fl) (79). We examined cardiac function in detail, using ECHO and invasive left 79	
heart catheterization at postnatal age day 30 ±5, 45 ±4 and 65 ±5. These groups represented pre-, 80	
mid- and late heart disease according to previous reports (77). There were no functional or 81	
anatomic differences between hearts of FXN KO and control mice at day 30 (Table 2-1).  82	
 Cardiac hypertrophy is manifest by day 45 in FXN KO animals (Table 2-1, Figure 2-1). 83	
Compared to controls, day 45 FXN KO mice have thickened left ventricular (LV) posterior walls 84	
in diastole (LVPWd) (FXN KO = 0.82 ±0.12 mm vs. FXNfl/fl = 0.64 ±0.08 mm; p<0.001), 85	
increased relative wall thickness (RWT) (FXN KO = 0.42 ±0.07 vs. FXNfl/fl = 0.33 ±0.05; 86	
p=0.002). FXN KO at day 45 also show findings consistent with both cardiomegaly and 87	
hypertrophy with increased ECHO-derived LV:body (FXN KO = 5.1 ±0.9 vs. FXNfl/fl = 3.9 ±0.7; 88	
p=0.004) and gross heart (mg):body weight (g) ratios (FXN KO: 5.90 ±1.70 vs. FXNfl/fl: 4.41 89	
±0.42; p=0.021). 90	
 Diastolic dysfunction occurs early, is concomitant with presentation of LV hypertrophy, 91	
and is persistent in FXN KO hearts. FXN KO mice demonstrate multiple relaxation abnormalities 92	
at day 45 (Table 2-1, Figure 2-1 & 2-2). Mitral blood flow velocity ratio of Early-to-Atrial waves 93	
(E/A) on Doppler imaging is increased at day 45 (FXN KO = 2.4 ±0.8 vs. FXNfl/fl = 1.5 ±0.2; 94	
p=0.003) and 65 (FXN KO = 3.7 ±1.4 vs. FXNfl/fl = 1.4 ±0.2; p<0.001), as well as isovolumic 95	
relaxation time (IVRT) at day 45 (FXN KO = 26.8 ±1.2 ms vs. FXNfl/fl = 23.9 ±2.3 ms; p=0.008) 96	
and day 65 (FXN KO = 33.6 ±4.2 ms vs. FXNfl/fl = 21.9 ±2.5 ms; p<0.001). Left ventricle 97	
relaxation rate (-dP/dt) is decreased in FXN KO compared to controls at days 45 (FXN KO = - 98	
6,087 ±1,378 mmHg/sec vs. FXNfl/fl = -9,704 ±799 mmHg/sec; p<0.001) and 65 (-4,099 ±1,104        99	
mmHg/sec vs. FXNfl/fl = -9,228 ±891 mmHg/sec; p<0.001). Finally, Tau, the LV relaxation time 100	
constant, is increased in FXN KO compared to controls at both day 45 (Tau Weiss: FXN KO = 101	
7.81 ±1.22 vs. FXNfl/fl = 4.53 ±0.57 ms, p<0.001) and 65 (Tau Weiss: FXN KO = 7.81 ± 0.95 vs. 102	
FXNfl/fl = 4.99 ±0.50 ms, p<0.001), demonstrating prolonged relaxation phase in diastole.  103	
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 104	
 105	
 106	
 107	
     108	
 109	
Heart function as measured by left heart catheterization and echocardiography 
 30 45 65 
 FXNfl/fl FXN KO FXNfl/fl FXN KO FXNfl/fl FXN KO 
CATH n = 7 n = 9 n=7 n=6 n=7 n=7 
Age (day) 30.7 ±1.8 31.9 ±2.9 46.9 ±0.9 44.8 ±0.4** 63.6 ±3.8 64.6 ±3.4 
HR (bpm) 605.3 ±85.3 577.1 ±44.6 671.4 ±95.2 580.9 ±81.4 595 ±77.1 643.3 ±105.2 
EF (%) 56.0 ±9.8 49.7 ±7.4 40.9 ±11.8 48.8 ±6.7 50.2 ±6.1 25.2 ±9.5*** 
+dP/dt (mmHg/s) 1015 ±1848 8760 ±962 11882 ±1928 6875 ±1156*** 10809 ±1591 5165 ±1101*** 
-dP/dt (mmHg/s) -8114 ±1067 -7802 ±817 -9704 ±799 -6087 ±1378*** -9228 ±891 -4099 ±1104*** 
MaxPwr 107.5 ±31.2 84.7 ±14.5 143.3 ±32.1 67.5 ±20.7*** 121.2 ±31.5 37.3 ±14.1*** 
Tau (Weiss) (ms) 5.3 ±1.0 5.6 ±0.5 4.5 ±0.6 7.8 ±1.2*** 5.0 ±0.5 7.8 ±1.0*** 
Tau (Mirsky) (ms) 8.7 ±1.5 8.4 ±1.0 8.4 ±0.9 11.0 ± 1.3** 8.6 ± 1.0 10.9 ± 1.5** 
ESP (mmHg) 88.6 ±10.2 87.4 ±9.7 103.2 ±5.4 87.7 ±11.9* 99.5 ±7.3 65.2 ±11.0*** 
EDP (mmHg) 11.7 ±4.5 11.0 ±3.3 10.9 ±3.8 13.0 ±5.7 8.8 ±3.0 10.0 ±5.3 
ESV (µl) 22.9 ±7.9 23.1 ±5.1 26.6 ±10.7 24.8 ±5.9 26.8 ±6.9 74.7 ±15.7*** 
EDV (µl) 50.9 ±6.6 45.7 ±7.3 43.6 ±12.2 48.2 ±9.0 53.4 ±7.8 99.6 ±15.2*** 
 FXNfl/fl FXN KO FXNfl/fl FXN KO FXNfl/fl FXN KO 
ECHO n=10 n=10 n=11 n=10 n=9 n=9 
BW (g) 15.6 ±3.0 13.5 ±3.7 20.4 ±2.0 21.3 ±1.7 23.7 ±2.4 22.4 ±1.2 
EF (%) 55.0 ±10.1 54.2 ±7.3 49.9 ±13.7 45.9 ±8.0 47.7 ±8.2 23.9 ±12.5*** 
FS (%) 28.2 ±6.4 27.6 ±5.0 25.6 ±9.2 22.7 ±4.6 23.7 ±4.9 11.1 ±6.0*** 
CO (ml/min) 19.7 ±7.2 18.9 ±8.1 17.4 ±5.1 16.8 ±4.6 21.4 ±4.9 13.2 ±5.1* 
CI (ml/min/g) 1.2  ±0.3 1.4 ±0.4 0.87 ±0.27 0.80 ±0.24 0.89 ±0.16 0.58 ±0.23* 
LVIDd (mm) 3.6 ±0.3 3.6 ±0.4 3.9 ±0.3 3.9 ±0.4 3.91 ±0.14 4.49 ±0.56** 
LVPWd (mm) 0.61 ±0.12 0.58 ±0.14 0.64 ±0.08 0.82 ±0.12*** 0.62 ±0.13 0.85 ±0.22* 
RWT 0.35 ±0.10 0.32 ±0.10 0.33 ±0.05 0.42 ±0.07** 0.32 ±0.07 0.39 ±0.13 
LV:body 4.1 ±1.4 4.5 ±1.6 3.9 ±0.7 5.1 ±0.9** 3.47 ±0.70 5.71 ±1.19*** 
E/A 1.6 ±0.2 1.7 ±0.2 1.5 ±0.2 2.4 ±0.8** 1.4 ±0.2 3.7 ±1.4*** 
IVRT (ms) 25.1 ±3.0 23.6 ±3.4 23.9 ±2.3 26.8 ±1.2** 21.9 ±2.5 33.6 ±4.2*** 
Table 2-1: Heart function as measured by ECHO and invasive left heart catheterization for FXN KO 
and controls at ages 30, 45 and 65 days. *=p<0.05, **=p<0.01, ***p=<0.001. HR = heart rate; EF = 
ejection fraction; +dP/dt = rate of contraction; -dP/dt = rate of relaxation; maxPwr = maximum power 
left ventricle; Tau (Weiss) = regression of log(pressure); Tau (Mirsky) = time required for LV pressure 
to fall to one-half of its value at end systolic pressure; ESP = end systolic pressure; EDP = end diastolic 
pressure; ESV = end systolic volume ; EDV = end diastolic volume; BW = body weight; FS = fractional 
shortening; CO = cardiac output; CI = cardiac index; LVIDd = LV internal diameter in diastole; 
LVPWd = LV posterior wall thickness in diastole; RWT = relative wall thickness; E/A = mitral blood 
flow velocity ratio of Early-to-Atrial waves; IVRT = isovolumic relaxation time.	
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 110	
FXN KO mice transition to dilated cardiomyopathy and heart failure   111	
  112	
 Contractility abnormalities occur in FXN KO mice as early as postnatal day 45 on 113	
invasive measurements, with progressive decline in systolic indices on day 65 measurements 114	
Figure 2-1. FXN KO mice exhibit left ventricular hypertrophy and diastolic dysfunction and 
transition to dilated cardiomyopathy and heart failure. FXN KO mice demonstrate cardiac 
hypertrophy at ages 45 and 65 days on (a) ECHO-derived left ventricle:body mass ratio (LV:body) and 
(b) left ventricular posterior wall thickness in diastole (LVPWd). Diastolic indices in the FXN KO mice 
are abnormal; with increases in (c) mitral valve Doppler flow ratio (E/A) and (d) isovolumic relaxation 
time (IVRT), and (e) decreased rate of left ventricle relaxation (-dP/dt). (f) FXN KO (days 45 and 65) 
had significantly slower rates of contraction (+dP/dt) and (g) maximum left ventricular power 
(maxPower) compared to FXNfl/fl controls. (h) FXN KO mice demonstrate significantly depressed 
global contractility function compared to controls for ejection fraction (EF, %) and (i) fractional 
shortening (FS, %). E/A = ratio of the early (E) to late (A) ventricular filling velocity; -dP/dt = -∆intra-
ventricular pressure/∆time; +dP/dt = +∆intra-ventricular pressure/∆time.  *=p<0.05	
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(Table 2-1, Figure 2-1 & 2-2). At day 45, FXN KO mice have a significant decrease in maximum 115	
ventricular power (maxPower) compared to controls (FXN KO = 67.5 ±20.7 mWatt vs. FXNfl/fl = 116	
143.3 ±32.1 mWatt; p<0.001) as well as rate of contraction (+dP/dt) (FXN KO = 6,875 ±1,155 117	
mmHg/sec vs. FXNfl/fl = 11,882 ±1,928 mmHg/sec; p<0.001). Again, at day 65, FXN KO mice 118	
demonstrate significantly depressed contractility (+dP/dt) (5,165 ±1,100 mmHg/sec) compared to 119	
control mice (10,809 ±1,591 mmHg/sec) (p<0.001) in addition to decreased maxPower (FXN KO 120	
= 37.3 ± 14.1 mWatt vs. FXNfl/fl = 121.2 ± 31.5 mWatt; p<0.001).  121	
 FXN KO mice progress to overt systolic heart failure on ECHO by postnatal day 65. 122	
Compared to controls, FXN KO animals have significantly reduced EF (FXN KO = 23.9 ±12.5% 123	
vs. FXNfl/fl = 47.7 ±8.2%, p<0.001) and fractional shortening (FS) (FXN KO = 11.1 ±6.0% vs. 124	
FXNfl/fl = 23.7 ±4.91%, p<0.001). FXN KO mice at day 65 also demonstrate reductions in both 125	
cardiac output (CO) (FXN KO = 13.2 ±5.1 ml/min vs. FXNfl/fl = 21.4 ±4.9 ml/min, p = 0.010) and 126	
cardiac index (CI) (FXN KO = 0.58 ±0.23 ml/min/g vs. FXNfl/fl = 0.89 ±0.16 ml/min/g, p = 127	
0.014) compared to controls.  128	
 Consistent with previous reports (77, 79), dilated cardiomyopathy is present in the FXN 129	
KO at day 65. There is a significant increase in LV internal diameter in diastole (LVIDd), in FXN 130	
KO (4.49 ±0.56 mm) compared to FXNfl/fl (3.91 ±0.14 mm) (p=0.006), providing evidence of a 131	
dilated LV. Further, the end-cycle blood volumes of the chamber in diastole are markedly 132	
increased in FXN KO at 65 days. Left ventricle end-diastolic volume (EDV) data collected with 133	
catheter-based direct volume measurements show that day 65 FXN KO mice have an increased 134	
EDV that is almost twice that of FXNfl/fl (99.7 ±15.2 µl vs. 52.7 ±8.29 µl, respectively; p <0.001), 135	
causing a dramatic rightward-shift in their pressure-volume curves (Table 2-1, Figure 2-2).   136	
 FXN KO mice at 65 days of age maintain earlier findings of cardiomegaly on ECHO- 137	
derived LV:body weight ratios (5.71 ±1.19) compared to FXNfl/fl mice (3.47 ±0.70) (p<0.001). 138	
FXN KO mice at day 65 also demonstrated close to a 50% increase in gross heart:body weight 139	
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ratio (8.81 ±1.5) than that measured at day 45 (5.90 ±1.7), and significantly higher than age- 140	
matched controls (4.70 ±0.26) (p<0.001) (Table 2-1, Figure 2-1).    141	
 142	
 143	
Acetylation is rapidly and temporally progressive and strongly correlates with a decline in heart 144	
function 145	
  146	
 We previously demonstrated that acetylation in the conditional FXN KO heart is 147	
dramatically increased in late stages of heart disease and that the majority of protein acetylation 148	
was localized to mitochondria (76). Here, we examined the level of lysine acetylation in heart 149	
tissue at each time point in which we measured cardiac function in order to determine the level of 150	
cardiac protein lysine acetylation relative to the evolution of cardiac dysfunction from pre-disease 151	
to overt heart failure.  152	
 We show that acetylation is modestly increased prior to onset of detectable cardiac 153	
dysfunction in the FXN KO heart at day 30. This is followed by a dramatically rapid and 154	
progressive increase in protein acetylation compared to controls (2-3a). We measured the 155	
expression levels of several essential mitochondrial electron transport proteins, and as expected, 156	
based on the established role of FXN in Fe-S cluster enzyme assembly (73, 80) and prior studies 157	
(76), the expression of ETC complex subunits CI-NDUFA9, CII-SDBH and CIII-Rieske is 158	
reduced in FXN KO and decreases consistently over this time course (Figure 2-3).   159	
 Surprisingly, when the level of acetylation was correlated with measured cardiac 160	
function, there was a strong inverse correlation between amount of acetylation, as measured by 161	
relative density on western blot imaging, and EF (r = -0.923) and FS (r = -0.927) (Figure 2-3). To 162	
demonstrate that mitochondrial deacetylase activity is decreased or absent in the FXN KO hearts, 163	
we probed for acetylation of known SIRT3 mitochondrial protein targets, SOD2 and LCAD.  164	
  165	
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Figure 2-2. FXN KO mice exhibit diastolic dysfunction followed by dilated cardiomyopathy and 
heart failure. (a) Representative mitral valve Doppler flow patterns (ratio of the early (E) to late (A) 
ventricular filling velocity, E/A) demonstrate restrictive cardiomyopathy in FXN KO at days of age 45 
and 65. (b) Echocardiographic parasternal short axis M-mode images demonstrate progressive 
impairment in left ventricle wall movement with decreased fractional shortening (FS) in FXN KO. (c) 
Parasternal axial images illustrate dilated cardiomyopathy with increased left ventricular internal 
diameter in diastole (LVIDd) in FXN KO at day 65. (d) FXN KO pressure volume loops represent 
increased end-diastolic volume (EDV) at day 65 compared to controls (p<0.001) with notable rightward 
shift of pressure-volume curves. Values indicated in (a), (b) and (c) are averages per group.  	
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SOD2 acts to destroy superoxide radicals and is inhibited when acetylated at lysine 68. SIRT3 167	
reverses acetylation (34, 81). LCAD is a key enzyme in fatty acid oxidation and reports have 168	
demonstrated increased activity in response to deacetylation by SIRT3 (39, 82). As expected, we 169	
detected increased acetylation of both SOD2 and LCAD in the FXN KO compared to controls 170	
(Figure 2-3), confirming decreased activity of SIRT3 deacetylase. These results are consistent 171	
with prior studies in our lab that demonstrated hyper-acetylation of SIRT3 targets in cardiac- 172	
specific FXN KO hearts, including AceCS2, LCAD, and MCAD (78). 173	
 174	
 175	
Abnormal cardiac mitochondria ultrastructure is accompanied by mitochondrial respiratory 176	
inhibition 177	
  178	
 Consistent with previous reports (55, 77), we found that pathologic changes in 179	
mitochondria become evident on electron microscopy (EM) as early as postnatal day 30 in 180	
ventricular tissue of FXN KO, and increase in prevalence over time (Figure 2-4). Mitochondrial 181	
ultrastructure changes in FXN KO hearts include loss and collapse of cristae, disordered 182	
mitochondria-to-sarcomere arrangement, and extensive accumulation and stacking of 183	
mitochondria, in addition to widespread electron-dense inclusions at day 65.  184	
 We quantified these observed morphological changes by measuring the ratio of 185	
myofibril-to-mitochondria area from micrographs, and determined the percentage of abnormal 186	
mitochondria in each strain (83). At day 65, the myofibril-to-mitochondria ratio was significantly 187	
decreased in FXN KO (0.90 ± 0.46) compared to controls (1.89 ±0.47) (p=0.011), and the 188	
average percentage of mitochondrial area containing abnormal mitochondria in FXN KO 189	
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 190	
 191	
 192	
 193	
 194	
 195	
 196	
Figure 2-3. Acetylation is increased and progresses with age in FXN KO, and correlates with 
worse heart function. Whole cell preparations or mitochondrial isolates from ventricular tissue were 
probed for proteins of interest as indicated. (a) Acetylation of lysine residues is increased early and 
progresses with age, and expression of electron transport chain complex subunits decreases in FXN KO 
hearts. (b) Plot of correlation between acetylation and systolic indices of heart function shows negative 
correlation between level of acetylation and ventricular function. (c) FXN hearts at day 65 had 
significantly increased total mitochondrial protein lysine acetylation (p=0.0339), increased acetylation 
of SOD2 at Lys-68 (AcK-SOD2) (p=0.0016) and (d) increased acetylation of LCAD compared to 
controls (p=0.0291). EF = ejection fraction, FS = fractional shortening. 	
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         197	
Figure 2-4. Abnormal cardiac mitochondria ultrastructure is accompanied by respiratory inhibition 
in FXN KO hearts. (a) Representative images from electron micrographs of cardiomyocytes viewed at 
11,000x. Mitochondrial ultrastructure abnormalities were apparent in FXN KO sections and progressed 
from days 30 to 65. Findings included matrix density loss, mitochondrial-to-sarcomere disarrangement, 
and accumulation and clumping of mitochondria. FXN KO day 65 mitochondria demonstrate cristae 
collapse and dissolution, and hyperdense inclusions. Arrowhead = collapsed cristae; arrow = electron-
dense intramitochondrial inclusions. (b) Myofibril:mitochondria area ratios were significantly decreased at 
day 65 in FXN KO compared to controls (n=3-8 micrographs per group). (c) Mitochondrial functional 
assays demonstrated significantly decreased respiratory control ratios in FXN KO (pooled mitochondria 
from n=8-12 hearts) compared to controls (pooled mitochondria from n=4-6 hearts).	
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(78.1±26.7%) was significantly higher than in control micrographs in which no abnormalities 198	
were detected (p=0.002) (Figure 2-4).  199	
 We next examined mitochondrial respiratory function at day 65. Respiratory control 200	
ratios (RCR) in FXN KO cardiac mitochondria (1.67 ±0.12) were significantly decreased 201	
compared to controls (4.86 ±0.37) (p<0.001) when measured by Clark Oxygen electrodes using 202	
complex I substrates glutamate and malate (2-4).  203	
 204	
 205	
FXN KO hearts exhibit features of maladaptive ventricular remodeling  206	
  207	
 Consolidated areas of fibrotic infiltration of the heart are widespread in FXN KO mouse 208	
hearts at day 65 (Figure 2-5), similar to previous reports (79). By measuring the percent of 209	
collagen detected in ventricular tissue on stained micrographs, we demonstrate that FXN KO 210	
mice have more than a 1.5 times increase in fibrotic involvement of ventricular tissue compared 211	
to controls (FXN KO = 9.1% vs. control 4.9%, p=0.002) (Figure 2-5). We did not find a 212	
significant increase in amount of collagen in the FXN KO hearts compared to controls at days 30 213	
or 45 on histological examination. FXN KO hearts at day 65 also display diffuse cardiomyocyte 214	
degeneration, indicated by the presence of vacuolation on light microscopy (Figure 2-5). 215	
Degenerating cardiomyocytes were not detectable at earlier ages (data not shown).  216	
 217	
 218	
Loss of FXN in the heart leads to cardiac steatosis and cold intolerance  219	
  220	
 Ventricular tissue of FXN KO at day 65 demonstrated a combined pattern of macro- and 221	
microsteatosis in cardiomyocytes (Figure 2-6), providing direct evidence of a defect in fat 222	
metabolism or utilization in these hearts.  223	
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 Because mice with loss of MCAD, or VLCAD in the heart quickly become hypothermic 224	
when exposed to cold environment and die (84, 85), and, similarly, ablation of SIRT3 leads to 225	
cold intolerance (82), we predicted that the conditional FXN KO would be unable to maintain its 226	
core body temperature when exposed to a cold stress. Mice were fasted for 6 hours then placed in 227	
a cold room at 4°C with core body temperature monitoring every 30 minutes, for a total period of 228	
180 minutes. Indeed, we found that cold exposure lead to a precipitous drop in body temperature 229	
and significantly decreased survival rate in the FXN KO animals compared to controls (Figure 2- 230	
6). The majority of the FXN KO animals expired or became moribund with body temperatures 231	
<19°C (at which time animals were euthanized for humane reasons) prior to cessation of the three 232	
hour time period (Figure 2-6). Both controls and FRDA mice were observed to be shivering with 233	
exposure to cold. 234	
  235	
 236	
 237	
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 238	
Figure 2-5. FXN KO hearts exhibit features of maladaptive ventricular remodeling. (a) Cardiac 
fibrosis is progressive in the FXN KO heart. Ventricular tissue was stained using Masson’s Trichrome 
to detect blue-staining fibrous tissue. (b) Percent area collagen was significantly increased in FXN KO 
hearts at postnatal day 65 compared to controls. (c) Evidence of cardiomyocyte degeneration in the 
FXN KO at day 65 is demonstrated by vacuolation on H&E staining.  	
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 242	
 243	
 244	
Figure 2-6. Loss of FXN in the heart leads to cardiac steatosis and cold intolerance. (a) FXN KO 
hearts demonstrate lipid accumulation in their hearts on Oil Red O staining. (b) Mice were subjected to 
a 6-hour fast after which they were placed in 4°C room for 3 hours with core body temperature 
monitoring. (c) FXN KO mice were unable to maintain core body temperature upon cold exposure and 
suffered significantly increased cold-related mortality rates compared to controls.  	
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Discussion 245	
  246	
 This study is the first to document the progression of lysine-acetylated proteins and to 247	
demonstrate a correlation between acetylation and cardiac function in the heart of the conditional 248	
FXN KO mouse model of FRDA heart disease. We have characterized the early stages of 249	
cardiomyopathy in this important mitochondrial disease and followed its evolution to late-stage 250	
heart failure using an established animal model, that which mirrors that of the FRDA human heart 251	
disease. We conclude that protein lysine acetylation increases in a temporally progressive pattern 252	
and that there is a strong negative correlation between level of acetylation in the heart and global 253	
heart function: as acetylation increases, ejection fraction and fractional shortening decrease.  254	
 We found that abnormal post-translational modification of key metabolic enzymes has 255	
occurred prior to detectable impairment in heart function in the FXN KO. Acetylation is 256	
increased at day 30 and continues to progress over time. The first notable abnormal traits on 257	
cardiac pathophysiology occur at 45 days of age, with thickening of the left ventricular wall and 258	
diastolic dysfunction. As acetylation progresses, heart function continues to decline and 259	
demonstrates features of decompensated left ventricular dilation, decreased ejection fraction and 260	
fractional shortening, consistent with systolic heart failure. These results suggest that targeting 261	
acetylation early would provide the best chance to halt or slow progression of FRDA heart 262	
disease. Modifying acetylation only after detectable cardiac dysfunction occurs may miss the 263	
opportunity to prevent irreversible hemodynamic changes in the FXN KO heart that leads to heart 264	
failure.  265	
 Loss of SIRT3 in other murine models results in maladaptive ventricular remodeling in 266	
response to stress (42), abnormalities in lipid metabolism, and reduced tolerance to cold exposure 267	
(82). We found similar outcomes in the FXN KO, which has dysfunctional SIRT3 activity. This 268	
implies that loss of function of SIRT3 in the FXN KO heart and resultant hyper-acetylation of 269	
SIRT3 target proteins plays a major role in the pathologic processes of FRDA mitochondrial heart 270	
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disease. The absence of FXN in the heart, which has an established role in manufacturing of Fe-S 271	
cluster subunits needed for enzymes vital to oxidative metabolism, is, in and of itself, a major 272	
insult to the cardiomyocyte cellular milieu (86). The conditional FXN KO model thereby acts as a 273	
“stressed heart” model to examine the role of acetylation in heart disease and failure. This is 274	
supported by our observation that changes seen in the FXN KO are more robust, with an earlier 275	
age at onset, than those seen in models of SIRT3 loss alone. SIRT3 activity is impaired in FRDA 276	
hearts likely due to the decreased bioavailability of NAD+ and to oxidative damage of SIRT3 277	
(76). The findings in this study can be applied to other models of heart disease and failure. Many 278	
cardiac diseases with abnormal metabolism and energy homeostasis are liable to result in 279	
impaired SIRT3 activity in a manner similar to the FXN KO model, leading to abnormal 280	
mitochondrial protein acetylation in the heart and impaired cardiac function. Such heart disease 281	
candidates include inherited mitochondrial cardiomyopathies, diabetic and metabolic syndrome 282	
heart disease, acquired cardiac hypertrophy, age-related and ischemic heart disease, and heart 283	
failure (42, 71). For example, the ischemic heart results in a shift in redox state with accumulation 284	
of NADH (87), mirroring the consequential disturbance in energy equivalents in the FRDA heart.  285	
 More studies are needed in order to determine a causative role of abnormal acetylation in 286	
leading to impairment of hearts with FXN loss. For instance, it would be of great interest to 287	
determine whether normalizing the NAD+/NADH ratio in the FXN KO heart would stimulate 288	
SIRT3 function, recover activity of targeted metabolic enzymes, and improve measured cardiac 289	
outcome. Recent work has shown that exogenous treatment with NAD+ precursors can increase 290	
NAD+ levels in mitochondria, reduce protein acetylation, and activate sirtuins (58, 59). Together 291	
with our findings that mitochondrial protein acetylation impairs heart function, this represents an 292	
attractive therapeutic potential for pharmacological modulation of protein lysine acetylation to 293	
improve cardiac metabolism and physiologic function and prevent unremitting progressive heart 294	
disease.  295	
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 One limitation of this study may be that the MCK promoter used to drive Cre expression 296	
in this model is expressed in all sarcomeric tissues, including skeletal muscle. It is not expected 297	
that loss of FXN in skeletal muscle would significantly alter cardiac function in this study. 298	
Indeed, in patients with FRDA, and in the original report of this mouse model (79), there is not an 299	
identified skeletal muscle phenotype. Using the cardiac-specific alpha myosin heavy chain 300	
promoter (α-MHC) would address this limitation. However, we determined that the MCK 301	
promoter was the logical choice for these experiments both because the α-MHC has also been 302	
noted to be cardio-toxic under certain conditions (88), and we wanted to avoid this as a 303	
confounding variable, and because the MCK-Cre transgene has been used extensively in our lab 304	
and others’ to generate the FXN KO mouse (76, 79).  305	
 In conclusion, we demonstrate a close relationship between mitochondrial protein 306	
acetylation, cardiac dysfunction and metabolic disruption in a model of FRDA hypertrophic 307	
cardiomyopathy. Our results suggest that abnormal acetylation contributes to the pathophysiology 308	
of heart disease in FRDA and may represent a therapeutic target for early intervention.  309	
 310	
  311	
Methods 312	
 313	
Mouse breeding and genotyping. This study was approved by the Institutional Animal Care and 314	
Use Committee of Indiana University. We used site-specific Cre-lox recombination to carry out 315	
gene deletions of interest. We used FXNfl/fl mice to create FXN KO mice that were homozygous 316	
for heart and skeletal muscle deletion of FXN (MCK-Cre:FXN KO), as previously published 317	
(79). Data was collected from males at postnatal days 30(±5), 45(±4), and/or 65(±5). Controls 318	
were age- and sex-matched healthy littermates (FXNfl/fl).  319	
  320	
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Echocardiography (ECHO). Transthoracic ECHO images were obtained using a VisualSonics® 321	
2100 ultrasound machine for small animal imaging and MS400 transducer (Fujifilm 322	
VisualSonics, Inc., Toronto, Canada). Functional parameters of the left ventricle and outflow 323	
tracts were measured using standard assessment techniques. Relative wall thickness (RWT) was 324	
calculated by (2*LVPWd)/LVIDd). 325	
 326	
Cardiac Catheterization. A 1.2 F catheter (Scisense, Transonic Systems Inc.) was inserted into the 327	
right carotid artery and advanced retrograde into the left ventricle. The Advantage system 328	
(Scisense, Transonic Systems Inc.) was used to acquire pressure, admittance, phase shift, and 329	
amplitude, and real time pressure-volume data was displayed and analyzed using Labscribe 2 330	
(iWorx, Dover, NH).  331	
 332	
Cold stress. This experiment was modeled after similar studies (84, 85). 65 day old FXN KO 333	
(n=5) and FXNfl/fl  (n=6) were selected for cold exposure. Mice were deprived of food for 6 hours 334	
prior to onset of study and for the duration of experiment. A baseline rectal temperature was 335	
taken prior to placement in 4°C cold room and then every 30 minutes thereafter for a total of 3 336	
hours. A study was terminated for humane reasons if core body temperature reached 19°C or less.  337	
  338	
Histology. Ventricular tissue selected for histology was fixed in 10% formalin and paraffin 339	
embedded. Histological analysis included hematoxylin and eosin (H&E) and Masson’s Trichrome 340	
to detect collagen as a measure of fibrosis. Collagen quantification was performed using ImageJ 341	
(IJ1.46) to measure percent area of tissue positively stained for collagen. Three to five 20x digital 342	
micrographs were obtained from each tissue section that underwent quantification studies.  343	
  344	
Electron Microscopy (EM). Ventricular tissue selected for electron microscopy was fixed in 2.5% 345	
glutaraldehyde and underwent sectioning and uranyl acetate staining by the Electron Microscopy 346	
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Center of Indiana University School of Medicine. At least 3 separate sections from each animal 347	
strain were selected for quantification analysis. Quantification methods were similar to methods 348	
used in our previous work (83). Abnormal mitochondria were identified as those containing 349	
electron-dense inclusions, cristae loss or dissolution, and/or collapsed or condensed cristae. 350	
Mitochondria and myofibril area was measured using ImageJ (IJ1.46).  351	
  352	
Isolation of Cardiac Mitochondria. Mitochondrial isolation followed the method described in our 353	
previous work (76). Freshly harvested hearts were submerged in ice-cold mitochondrial isolation 354	
buffer. Heart tissue was weighed, homogenized, and then subjected to differential centrifugation. 355	
The mitochondrial pellet was resuspended in the appropriate buffer and used immediately for 356	
respiration assay or western blotting, or flash frozen for later analysis.  357	
  358	
Mitochondrial respiration. Mitochondrial isolates designated for use in respiration assays were 359	
resuspended in mitochondrial respiration buffer. A total of 2-3 mouse heart mitochondria were 360	
combined for each run, with n=4-6 pooled heart mitochondria assayed for controls and n=8-12 361	
pooled heart mitochondria assayed for FXN KO. A Clark-oxygen electrode was used for 362	
respiration assays. Glutamate and malate were used as a substrate for all assays.  363	
  364	
Antibodies and Western Blotting. Primary antibodies included anti-acetyl-lysine (Cell Signaling 365	
#9441), anti-SIRT3 (Cell Signaling #5490), anti-SOD2 (acetyl K68) (Abcam ab137037), anti- 366	
SOD2 (Cell Signaling #13141), anti-VDAC (Cell Signaling #4866), anti-GAPDH (Cell Signaling 367	
#5174), anti-FXN (generous gift of Grazia Isaya, Mayo Clinic, Rochester MN), anti-LCAD 368	
(Abcam ab196655) and to the electron transport chain complexes: anti-CI-NDUFA9 (Abcam 369	
ab14713), anti-CII-SDHB (Abcam ab14714) and anti-CIII-UQCRFS1 (Abcam ab14746). Band 370	
intensities were measured using ImageJ (IJ1.46). To determine correlation between acetylation 371	
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and heart function, relative density of acetylation for n=3 western blot images was normalized to 372	
day 30 controls and averages for each group were used for correlation calculation.  373	
  374	
Statistics.  All calculations, analyses and graphs were performed using SigmaPlot (Systat 375	
Software, Inc.). Two groups were compared using a two-tailed student’s t test for samples with 376	
equal variance. Final data are presented as mean (±SD). Alpha was set at 0.05 and power at 377	
0.800. A p-value of <0.05 was considered statistically significant. 378	
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CHAPTER 3 
 
LOSS OF SIRTUIN 3 ACCELERATES HEART FAILURE IN A MURINE MODEL OF 
FRIEDREICH’S ATAXIA MITOCHONDRIAL HEART DISEASE 
 
 
Introduction 
 
 The heart disease in Friedreich’s Ataxia (FRDA) results from inherited deficiency of 
frataxin (FXN), a mitochondrial protein important in energy homeostasis. FXN is a highly 
conserved mitochondrial matrix protein that functions in iron-sulfur cluster assembly, which is 
integral to mitochondrial metabolic machinery (73). Reduced expression of FXN in FRDA causes 
impaired energy generation, decreased NAD+/NADH ratio, and increased oxidative stress (9, 74, 
75). In addition to ataxia, patients almost universally exhibit cardiac complications, which are 
characterized by arrhythmias, hypertrophic cardiomyopathy and heart failure. Heart disease is 
responsible for the majority of death in FRDA (48). FRDA is a relentlessly progressive disease 
for which there is no cure.  
 Mitochondrial protein acetylation is a post-translational protein modification that 
functions as a key regulator of cardiac metabolism and appears to play an important role in heart 
disease (89-92). SIRT3 is responsible for regulating mitochondrial protein lysine acetylation in 
response to cellular energy status by NAD+-dependent deacetylation of its target proteins, which 
are typically activated in response to deacetylation (10-12). SIRT3 targets include metabolically 
active enzymes, such as those of fatty acid oxidation, pyruvate and acetate metabolism, and the 
electron transport chain (6, 16-19, 21-24, 93), as well as the mitochondrial reactive oxygen 
species scavenger, superoxide dismutase 2 (SOD2) (34-36). In the heart, SIRT3 provides 
protection from a variety of stressors, such as ischemia and ischemia/reperfusion injury and 
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mechanical stress (39-41) and has been shown to attenuate lipotoxic cardiomyopathy and 
pressure-overload hypertrophy (42-45). 
 In a conditional murine model of FRDA cardiomyopathy, mitochondrial proteins have 
increased acetylation and decreased activity of SIRT3 (9). This reduction in SIRT3 activity is 
likely due to insufficient NAD+ bioavailability as a result of dysfunctional energy metabolism by 
the FXN-depleted mitochondria. More recently, we demonstrated a temporally progressive level 
of mitochondrial acetylation in a conditional knockout model of FRDA heart failure and a strong, 
negative correlation between level of acetylation and cardiac function in these hearts (62).  
 Recent work has shown that exogenous treatment with NAD+ precursors can increase 
NAD+ levels in mitochondria to activate sirtuins and reduce protein acetylation (58, 59). NAD+ 
repletion has been shown, specifically, to increase SIRT3 activity and provide protection from 
cardiac injury (60). This represents an attractive therapeutic potential for pharmacological 
modulation of protein lysine acetylation to improve cardiac metabolism and physiologic function.  
 We propose that abnormal acetylation impairs heart function in the FRDA heart. To test 
this hypothesis, we modified acetylation in the FRDA murine model heart by ablating SIRT3 
gene expression altogether to create a double knockout mouse (FXN/SIRT3 DKO) and 
determined whether this led to changes at the cellular and molecular level to exhibit changes in 
cardiac pathophysiology when compared to FRDA and healthy controls. We also tested the 
hypothesis that NR therapy would normalize the NAD+/NADH ratio in the FXN KO heart, 
stimulate SIRT3 function to reduce acetylation levels and recover activity of targeted metabolic 
enzymes, and would result in improvement in measured cardiac outcome. 
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Results 
 
Subcellular location of protein acetylation 
  
 SIRT3 is established as the major deacetylase in mitochondria (70), however, the 
subcellular location of active SIRT3 in other compartments remains controversial (94). Because 
FRDA arises from a specific mitochondrial defect that leads to inactivation of mitochondrial 
SIRT3 and increased mitochondrial protein acetylation (9, 62), we suspected that the majority of 
protein acetylation in the FXN KO heart would be localized to the mitochondria. To test this 
hypothesis, we performed cellular fractionation to separate the mitochondria from cytosolic 
cellular components and probed each fraction for lysine acetylation. We were surprised to find 
that ablating SIRT3 in the heart results in a robust increase in both cytosolic and mitochondrial 
protein lysine acetylation (Figure 3-1). In fact, the majority of acetylated proteins are contained in 
the cytosolic compartment in the control, FXN KO and SIRT3 KO hearts, with the exception 
being the FXN/SIRT3 DKO. Our findings indicate that SIRT3 is important in regulating both 
cytosolic and mitochondrial lysine acetylation. We were also interested to detect SIRT3 in both 
cytosol and mitochondria. The precise cellular location of SIRT3 remains controversial. Some 
researchers have reported SIRT3 in multiple cellular compartments, including the nucleus, 
cytosol and mitochondria (95, 96), while others have documented exclusive mitochondrial SIRT3 
expression (10, 97).  
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Figure 3-1. Acetylation is increased in FXN/SIRT3 DKO hearts. Whole cell preparations or 
mitochondrial isolates from ventricular tissue were probed for proteins of interest as indicated. (a) 
comparison of acetylation between cytosolic and mitochondrial compartments.  (b) FXN/SIRT3 DKO 
acetylation compared to FXN KO mice at weeks 4, 7 and 10 shows increased acetylation at each time 
point in the FXN/SIRT3 DKO hearts. (c) Neither acetylation nor SIRT3 ablation affect the expression 
of electron transport chain proteins. (d) Proteins from isolated cardiac mitochondria were probed for 
SOD2 acetylated at Lys-68 (AcK-SOD2) to demonstrate increased acetylation of a specific SIRT3 
target protein in FXN KO and FXN/SIRT3 DKO mitochondria. 
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Acetylation in the FXN KO heart increases in the absence of SIRT3 expression 
 
  
 Acetylation increases in conditional FXN KO hearts with age and correlates with 
declining heart function (62). Hearts in FXN/SIRT3 DKO mice demonstrate a robust increase in 
protein acetylation compared to age-matched FXN KO hearts, and follow a temporally 
progressive acetylation in a manner similar to FXN KO hearts (Figure 3-1).  
 We used the acetylation state of a specific mitochondrial target of SIRT3 as readout for 
SIRT3 deacetylase activity. To confirm that SIRT3 deacetylase activity is absent in the FXN KO 
and FXN/SIRT3 DKO hearts, we probed for acetylation of SOD2, which is a known SIRT3 
protein target. SOD2 acts to destroy superoxide radicals and is inhibited when acetylated at lysine 
68. SIRT3 reverses SOD2 acetylation (34, 81). We detected increased acetylated SOD2 in both 
FXN KO and FXN/SIRT3 DKO cardiac mitochondria at similar levels compared to controls 
(79.9% and 78.7% increase, respectively) (Figure 3-1). This finding is consistent with the absence 
of SIRT3 deacetylase activity, leading to SOD2 inhibition in these hearts.   
 We next investigated the relationship between acetylation and expression of essential 
mitochondrial electron transport proteins in FXN KO and FXN/SIRT3 DKO hearts. We know 
that the expression of enzymes utilizing Fe-S cluster components decreases progressively in FXN 
KO hearts (62) which, in itself, impairs energy generation capacity. Because SIRT3 acts in a post-
translational manner and has not been shown to affect protein expression, we expected that 
deletion of SIRT3 would not affect the expression levels of essential mitochondrial electron 
transport proteins. Therefore, in order to verify that differences detected in the knockout hearts on 
cellular, molecular or functional levels result from loss of SIRT3-induced post-translational 
modifications of metabolically active proteins, and not from changes in SIRT3 target protein 
expression, we compared expression levels of ETC complexes in FXN KO and FXN/SIRT3 DKO  
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mice at week 10 with matched FXNfl/fl and SIRT3 KO controls to confirm that loss of FXN, and 
not loss of SIRT3 or increased protein acetylation, was responsible for the observed decrease in 
transport chain protein expression. As expected, (9, 62, 73), the expression of electron transport 
chain complex subunits CI-NDUFA9, CII-SDBH and CIII-Rieske is markedly diminished FXN 
KO hearts at 10 weeks of age, yet there were no differences in expression of electron transport 
chain subunits in the FXN KO compared to FXN/SIRT3 DKO at 10 weeks of age (Figure 3-1).  
 
 
 
 
 
Figure 3-2. Loss of SIRT3 increases cardiac fibrosis in the FXN KO heart. (a) Ventricular tissue 
underwent sectioning and staining for electron microscopy to examine mitochondrial ultrastructure (top 
panel). Ventricular tissue was stained with Masson’s trichrome to detect blue staining fibrosis (middle 
panel) or Oil Red O to detect lipids (bottom panel). (b) Cardiac fibrosis is significantly increased in 
FXN/SIRT3 DKO hearts.	
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FXN KO and FXN/SIRT3 DKO hearts demonstrate abnormal cardiomyocyte mitochondria 
ultrastructure 
  
 We next asked whether deletion of SIRT3 in the FXN KO heart would lead to a structural 
impact on the mitochondria at the organelle level. There is progressive loss of normal 
mitochondrial ultrastructure in the FXN KO heart, which is associated with increasing levels of 
acetylation (62). We used electron microscopy to compare ventricular tissue of 10-week FXN KO 
to FXN/SIRT3 DKO and controls. Widespread pathologic changes were observed in the 
cardiomyocyte mitochondria of FXN KO and FXN/SIRT3 DKO (Figure 3-2). Mitochondrial 
ultrastructure changes include loss and collapse of cristae, disordered mitochondria-to-sarcomere 
arrangement, and extensive accumulation and stacking of mitochondria, in addition to widespread 
electron-dense inclusions. We also observed abnormalities in the SIRT3 KO heart mitochondria 
with generalized loss of cristae at 10 weeks of age.  
 To quantify the observed mitochondrial features in the FXN KO and FXN/SIRT3 DKO, 
we measured the ratio of myofibril-to-mitochondria area from micrographs, and determined the 
percentage of abnormal mitochondria (62, 98). The myofibril-to-mitochondria ratio was 
significantly decreased in FXN KO (0.901±0.462) and FXN/SIRT3 DKO (0.771±0.195) 
compared to controls (1.89±0.471) (p=0.013), however, there was no significant difference 
between FXN KO ratio and FXN/SIRT3 DKO ratios (p=0.661) (Figure 3-2).  
 
 
Deletion of SIRT3 in the FXN KO heart increases cardiac fibrosis  
  
 Fibrotic infiltration of the heart arises within a diverse array of cardiac pathologies, and 
typically is a response to injury of healthy myocardium by replacement with deposition of 
collagen fibers. Abnormal accumulation of fibrosis in the heart leads to ventricular wall stiffness, 
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perfusion defects and electrophysiologic dysfunction (99). Fibrosis is widely prevalent in FXN 
KO hearts as they age, as previously published (62).  Here, we demonstrate that ventricular 
fibrosis is increased substantially in FXN/SIRT3 DKO hearts compared to FXN KO (Figure 3-2). 
Loss of SIRT3 expression in the FXN KO heart leads to more than a 1.5 times increase in fibrotic 
involvement of ventricular tissue as noted on histopathology (FXN KO = 9.1% vs. FXN/SIRT3 
DKO = 15.2% tissue field area composed of collagen, p<0.001).  
 Cardiac adiposity is known to be a marker of defective lipid metabolism in the heart and 
is associated with lipotoxic cardiomyopathy of diabetes, obesity-related heart disease and heart 
failure (100-103). We previously documented evidence of dysfunctional lipid metabolism in FXN 
KO hearts with the presence of cardiac steatosis (62). Here, we show similar areas of cardiac 
steatosis in the double knockout mouse heart (Figure 3-2). Mice with absence of SIRT3 
expression develop excessive lipid accumulation in the heart compared to controls in response to 
pressure overload stress (42). We found that, at baseline, 10 week-old conditional SIRT3 KO 
mice develop areas of abnormal lipid accumulation in their hearts. This provides evidence that 
loss of myocardial SIRT3 alone is sufficient to cause steatosis in the heart at 10 weeks of age, 
even in the absence of external stressors.  
 
 
Loss of SIRT3 increases protein acetylation and worsens heart failure in the FXN KO heart  
  
 We previously provided a detailed description of the progression from asymptomatic 
early-stage heart disease to end-stage heart failure in the FXN KO mouse. The FXN KO mouse 
heart is characterized by features that closely mirror the human FRDA heart disease such as early 
diastolic dysfunction and cardiac hypertrophy progressing rapidly to decompensated, dilated heart 
failure (62, 77). We established a strong negative correlation between heart function and level of 
cardiac mitochondrial protein acetylation, such that as acetylation levels increased, heart function 
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worsened (62). Considering the robust increase in mitochondrial protein acetylation in the double 
knockout heart, we were interested in determining what changes to pathophysiologic functional 
outcome would occur due to this increase.  
 
 
Acetylated knockout hearts are hypertrophic with early diastolic dysfunction  
 
Multiple anatomic parameters in the FXN KO and FXN/SIRT3 DKO mice are consistent 
with cardiac hypertrophy as early 7 weeks of age (Table 3-1). Week 7 FXN KO and FXN/SIRT3 
DKO mice have thickened left ventricular posterior walls in diastole (LVPWd) (FXN KO = 0.838 
±0.134 mm, FXN/SIRT3 DKO = 0.859 ±0.168 mm), increased relative wall thickness (RWT) 
(FXN KO = 0.439 ±0.085; FXN/SIRT3 DKO = 0.424 ±0.076), and increased gross heart:body 
weight ratio (FXN KO = 5.58 ±1.71, FXN/SIRT3 DKO = 5.77 ±1.04), compared to FXNfl/fl 
controls (LVPWd = 0.643 ±0.078 mm; RWT = 0.332 ±0.050; heart:body weight = 4.40 ±0.47). 
Knockout mice at week 7 also have increased ECHO-derived LV:body weight ratios (FXN KO = 
5.17 ±0.89 and FXN/SIRT3 DKO = 5.14 ±1.93) compared to FXNfl/fl mice (3.92 ±0.69).  
Diastolic dysfunction occurs early and precedes the onset of heart failure in the knockout 
models (Table 3-1). Both FXN KO and FXN/SIRT3 DKO mice demonstrate restrictive LV filling 
at 7 weeks of age, measured by increased mitral blood flow velocity ratio of Early-to-Atrial waves 
(E/A) on Doppler imaging (FXN KO = 2.36 ±0.83, and FXN/SIRT3 DKO = 2.82 ±0.86 
compared to FXNfl/fl controls = 1.56 ±0.22).  
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FXN KO and FXN/SIRT3 DKO hearts have persistent diastolic dysfunction with a transition to 
dilated cardiomyopathy. 
  
 Not surprisingly, both FXN KO and FXN/SIRT3 DKO mice demonstrate progressive 
cardiac dysfunction with relaxation abnormalities, cardiomegaly and dilated cardiomyopathy at 
10 weeks of age (Table 3-1 and 3-2, Figures 3-3 and 3-4). Mitral blood flow velocity ratio (E/A) 
remains elevated at 10 weeks of age (FXN KO = 3.80 ±1.45; FXN/SIRT3 DKO = 3.59 ±1.02, vs. 
FXNfl/fl controls = 1.37 ±0.15). Another marker of relaxation dysfunction, isovolumic relaxation 
time (IVRT), is increased at 10 weeks (FXN KO = 33.6 ±4.2 msec; FXN/SIRT3 DKO = 35.3 
±4.8 msec vs. FXNfl/fl controls = 21.9 ±2.5 msec). The presence of cardiomegaly is apparent at 10 
weeks by ECHO-derived LV:body ratio, which is greater in both FXN/SIRT3 DKO (8.00 ±2.82) 
and FXN KO mice (5.92 ±1.08) compared to controls (3.47 ±0.70). Left ventricle hypertrophy is 
also present with increased LVPWd in FXN KO (0.852 ±0.23 mm) and FXN/SIRT3 (0.853 ±0.23 
mm) compared to controls (0.62 ±0.13 mm).  
 Findings of LV dilatation are present in both knockout groups at 10 weeks of age. We 
found significant increases in LV internal diameter in diastole (LVIDd) in FXN KO (4.50 ±0.598 
mm) and FXN/SIRT3 DKO (5.06 ±0.562 mm) compared to FXNfl/fl (3.91 ±0.141 mm). LV 
volume at end-diastole derived with ECHO, used here to estimate end diastolic volume (EDV), is 
increased as well in FXN KO and FXN/SIRT3 DKO mice (94.7 ±29.7µl and 123.4 ±31.5µl, 
respectively) compared to controls (67.4 ±4.5µl). These findings are consistent with a transition 
from cardiac hypertrophy to dilated cardiomyopathy in the knockout hearts between 7 and 10 
weeks of age. 
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Loss of SIRT3 in the FXN KO heart increases protein acetylation and worsens heart failure   
  
 Deletion of SIRT3 in the FXN KO mouse exacerbates heart failure. FXN/SIRT3 DKO 
animals demonstrate significantly depressed global contractile function compared to the FXN KO 
animals on ejection fraction (EF) (FXN KO = 26.6 ±10.4%; FXN/SIRT3 DKO = 12.7 ±10.3%, p 
= 0.011) and fractional shortening (FS) (FXN KO= 12.4 ±5.01%; FXN/SIRT3 DKO = 5.77 
±4.79%, p=0.017). This is consistent with our previous findings that the level of acetylation 
negatively correlates with heart function, and with the established role of SIRT3 protection in the 
heart. 
 
  
Hypertrophic cardiomyopathy with conditional loss of SIRT3  
  
 Previous studies have reported cardiac hypertrophy in unconditional SIRT3 KO mice as 
early as 8 weeks of age, even in the absence of external stressors such as systemic pressure 
overload (25, 43). In order to confirm that conditional loss of SIRT3 in the heart, independent of 
FXN loss, would lead to similar findings of hypertrophy in non-stressed hearts at 10 weeks of age 
we compared the function of SIRT3 KO hearts to age-matched healthy SIRT3fl/fl control 
littermates (Table 3-3). Indeed, the SIRT3 KO heart shows the beginning stages of hypertrophic 
remodeling at 10 weeks of age. SIRT3 KO hearts have significantly thicker posterior walls, 
LVPWd, compared to SIRT3fl/fl (0.947 ±0.105 vs. 0.807 ±0.045 mm; p=0.003), as well as higher 
RWT (0.461 ±0.053 vs. 0.395 ±0.046; p=0.015). However, SIRT3 KO mice do not have 
increased LV:body weight (4.76 ±0.61 vs. 4.62 ±0.83; p=0.683) or heart:body weight compared 
to SIRT3fl/fl (5.14 ±0.22 vs. 5.07 ±0.47; p=0.697). 
  Consistent with LV hypertrophy, SIRT3 KO have decreased end diastolic volume (EDV) 
and increased end diastolic pressure (EDP) compared to SIRT3fl/fl at 10 weeks (SIRT3 KO = 
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30.15 ±9.28 uL vs. SIRT3fl/fl = 46.40 ±9.92 uL, p=0.006; and SIRT3 KO = 11.24 ±4.20 vs. 
SIRT3fl/fl = 5.66 ±3.14 mmHg, p=0.030, respectively). However, SIRT3 KO mice do not 
demonstrate significant diastolic abnormalities at this stage. Specifically, there are no differences 
compared to SIRT3fl/fl in -dP/dt (-8,582 ±1,725 vs. -9,718 ±1,113 mmHg/sec; p=0.132) or E/A 
(1.57 ±0.21 vs. 1.65 ±0.24; p=0.475). IVRT in SIRT3 KO (22.25 ±1.46 msec) was longer 
compared to SIRT3fl/fl (20.14 ±1.16 msec) but statistically similar to FXNfl/fl (21.92 ±2.49 msec).  
 Contractile function is preserved in 10 week old mice with isolated loss of SIRT3. There 
are no differences in rate of contraction (+dP/dt) compared to SIRT3fl/fl (11106 ±2679 vs. 13426 
±1939 mmHg/sec; p=0.0640) or global systolic function as measured by EF (56.7% ±11.55 vs. 
57.41% ±12.10; p=0.900) and FS (29.85% ±7.68 vs. 30.40% ±8.29%; p=0.8850).
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Pairwise comparison for hemodynamics and ECHO 
  FXNfl/fl FXNfl/fl FXN KO 
 vs. FXN KO FXN/SIRT3 DKO FXN/SIRT3 DKO 
4 
HR  * ** 
EDV  *  
EA†    
7 
Age * *  
+dP/dt *** **  
-dP/dt *** ***  
maxPwr *** ***  
LVPWd *** **  
RWT ** **  
EA * ***  
LV:body ** **  
10
 
+dP/dt ***   
-dP/dt ***   
maxPwr ***   
EDV ***   
EF *** *** * 
FS ** *** * 
LV Vol d * *  
LVIDd * ***  
LVPWd†    
EA *** ***  
IVRT *** ***  
LV:body * *  
 p-value: *=<0.05, **=<0.01, ***=<0.001 
Table 3-2. Pairwise comparison of heart function between 
groups. † Significance on ANOVA, but not on pairwise 
comparison analysis.  
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Figure 3-3. FXN KO and FXN/SIRT3 DKO heart function compared to controls. (a) FXN KO and 
FXN/SIRT3 DKO have cardiac hypertrophy (LVPWd) at weeks 7 and 10. (b) Total heart:body weight 
ratio is significantly increased at week 7 in FXN KO and FXN/SIRT3 DKO mice compared to FXNfl/fl 
controls and progressively increases to week 10. (c) ECHO-derived LV:body mass ratios are elevated in 
week 10 FXN KO and FXN/SIRT3 DKO animals compared to FXNfl/fl controls. (d) Relaxation 
abnormalities are apparent by increased E/A mitral flow ratios at weeks 7 and 10, and (e) isovolumic 
relaxation time (IVRT) at week 10 in FXN KO and FXN/SIRT3 DKO. (f) Left ventricle rate of 
relaxation (-dP/dt) is decreased compared to FXNfl/fl controls in FXN KO and FXN/SIRT3 DKO 
animals on week 7, and on week 10 in FXN KO. (g) Mitral flow patterns demonstrate restrictive E/A 
flow ratio. LVPWd = left ventricle posterior wall diastolic thickness (mm); LV = left ventricle; E/A = 
ratio of the early (E) to late (A) ventricular filling velocities; IVRT = isovolumic relaxation time (ms); -
dp/dt = rate of relaxation (-∆intra-ventricular pressure/∆time)(mmHg/sec). *=p<0.05; statistical 
significance between groups is indicated by lines connecting graph bars. 	
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Figure 3-4. Loss of SIRT3 in FXN KO hearts exacerbates heart failure. (a) and (b) FXN/SIRT3 
DKO demonstrate significantly depressed global contractility function compared to the FXN KO for EF 
(p = 0.027) and FS (p= 0.037). Catheterization data for FXN/SIRT3 DKO at 10 weeks is not present 
because the majority did not survive surgical catheterization (see text). (c) and (d) FXN/SIRT3 DKO 
and FXN KO had significantly slower rate of contraction (+dP/dt), and maxPower compared to FXNfl/fl 
controls. (e) Representative echocardiographic parasternal short axis M-mode images demonstrate 
progressive impairment in left ventricular wall movement with decreased fractional shortening in FXN 
KO and FXN/SIRT3 DKO. (f) Parasternal axial images illustrate findings of hypertrophy with 
transition to dilated cardiomyopathy in FXN KO and FXN/SIRT3 DKO mice. +dP/dt = rate of 
contraction (+∆intra-ventricular pressure/∆time)(mmHg/sec); *=p<0.05; statistical significance between 
groups is indicated by lines connecting graph bars. 
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Heart function of SIRT3fl/fl and SIRT3 KO at 10 weeks 
 
SIRT3fl/fl  SIRT3 KO   
 
n=9 n=7 
 CATH AVG AVG  p-value  
HR (bpm) 714.0 ±59.2 626.6 ±95.2 0.040 
+dP/dt (mmHg/sec) 13426 ±1934  11105.88 ±2678.6 0.064 
-dP/dt (mmHg/sec) -9718 ±1113 -8582 ±1725 0.132 
maxPwr (mWatt) 162.1 ±31.4 131.2 ±42.5 0.116 
EDP (mmHg) 5.8 ±4.6 11.2 ±4.2 0.030 
EDV (uL) 46.6 ±10.5 30.2 ±9.3 0.006 
 
SIRT3fl/fl SIRT3 KO   
  n=9 n=9 
 ECHO  AVG AVG  p-value  
EF (%) 57.4 ±12.1 56.7 ±11.6 0.900 
FS (%) 30.4 ±8.3 29.9 ±7.7 0.885 
LV:body (mg:g) 4.6 ±0.83 4.8 ±0.61 0.683 
LVIDd (mm) 4.1 ±0.42 4.1 ±0.33 0.983 
LVPWd (mm) 0.81 ±0.05 0.95 ±0.11 0.003 
RWT 0.40 ±0.05 0.46 ±0.05 0.015 
EA  1.7 ±0.24 1.6 ±0.21 0.475 
IVRT (msec) 20.1 ±1.2 22.3 ±1.5 0.020 
 
Table 3-3. Heart function of SIRT3fl/fl and SIRT3 KO 
at 10 weeks.	
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Loss of SIRT3 in the FXN KO heart increases stress-related mortality and rate of heart failure-
associated weight loss  
  
 We next wanted to determine whether the changes observed at the cellular and organ 
level after deletion of SIRT3 in the FXN KO heart had a broader impact on physiologic 
outcomes, such as lifespan and growth pattern. Both the FXN KO and FXN/SIRT3 DKO had 
significantly foreshortened average lifespans. The mean age at death in the FXN KO mice (n=11) 
was 86.6 ± 9 days, and the FXN/SIRT3 DKO mice (n=10) was 84.9 ±6 days (Figure 3-5). FXNfl/fl 
(n=11) were followed for 120 days of postnatal life and no deaths occurred in this group within 
this period. We found no difference in non-stressed survival between FXN KO and FXN/SIRT3 
DKO (p=0.724).  
 Weight loss begins at approximately 8 weeks of life in both FXN/SIRT3 DKO and FXN 
KO under unmodified conditions (Figure 3-5). Notably, the FXN/SIRT3 DKO mice lose weight 
at a significantly faster rate than the FXN KO animals (median rate (∆mass (gm)/∆time (weeks)): 
FXN KO = -0.061 vs. FXN/SIRT3 DKO = -0.147, p=0.003). This accelerated weight loss may 
arise from a steeper decline in heart function in the FXN/SIRT3 DKO mice when compared with  
 
 FXN KO mice. Consequently, the absence of SIRT3 expression in the double knockout appears 
to predispose the mice to a more aggressive onset of metabolic imbalance such as that seen in the 
wasting process of cardiac cachexia. 
 A final and remarkable physiologic outcome difference we found between the FXN KO 
and FXN/SIRT3 DKO mice was in their response to surgical intervention. The FXN/SIRT3 DKO  
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mice are significantly more susceptible to death from surgical stress than FXN KO mice under 
the same operative conditions. Surgical mortality was markedly increased in the FXN/SIRT3 
DKO (n=12) animals compared to FXN KO (n=17) (11 out of 12, or 90.9% vs. 4 out of 17, or 
30.8%; p=0.005, 95% CI=-0.969 to -0.234) (Figure 3-5). This observation suggests that hyper-
acetylation in the heart leads to an increase in procedural risk and may have relevance in the 
perioperative clinical setting.  
 
Figure 3-5. Loss of SIRT3 in FXN KO hearts increases operative mortality and accelerates weight 
loss. (a) There is no difference in overall non-stressed longevity between FXN KO (n=11) and 
FXN/SIRT3 DKO (n=10) (p=0.474). No deaths occurred in FXNfl/fl (n=11). (b) FXN/SIRT3 DKO 
(n=10) peak at a higher body weight, but have an increased rate of weight loss rom week 8 to 13 (∆mass 
(g)/∆time (weeks)) compared to FXN KO (median rate FXN KO = -0.054 vs. FXN/SIRT3 DKO = -
0.148, p<0.001). (c) Procedural mortality of FXN/SIRT3 DKO (n=12) is increased compared to FXN 
KO (n=17) at 65 days upon exposure to cardiac catheterization (p=0.005, 95% CI=-0.969 to -0.234). 	
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NAD+ replacement therapy with nicotinamide riboside increases mitochondrial protein 
acetylation and does not improve cardiac function in FXN KO mice  
  
 There is evidence that NAD+ repletion by oral supplementation with its precursor, 
nicotinamide riboside (NR), is effective at increasing mitochondrial NAD+ content, SIRT3 
activity and improving mitochondrial function (58). Because SIRT3 is inactive in the FXN KO 
mouse heart likely secondary to decreased bioavailability of NAD+ from deficient energy 
production, we expected that recovering the NAD+ level in these cells would act to stimulate 
SIRT3 function. We tested the hypothesis that oral NR therapy would normalize lysine 
acetylation and improve cardiac performance in the FXN KO mice. We administered oral NR at 
500 mg/kg/day to FXN KO mice (n=6) and healthy controls (n=6) from 4 weeks of age until 10 
weeks of age.  
 NR supplementation was effective at increasing NAD+ content in the hearts of treated 
animals (Figure 3-6). We were surprised to find that FXN KO hearts demonstrated increased 
global mitochondrial protein lysine acetylation in response to exogenous treatment with NR. 
SIRT3 protein expression in mitochondria responded to NR therapy by increased expression. 
Despite the increase in mitochondrial SIRT3 expression, the acetylation state of SOD2, a known 
target of SIRT3 and our readout for SIRT3 activity in this study, remained similarly elevated in 
both treated and untreated FXN KO mice compared to controls. SOD2 did not increase to the 
extent that global acetylation increased, suggesting that up regulated SIRT3 expression was able 
to counteract a measure of the increased acetylation.  
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 Cardiac function declined steadily with age in FXN KO animals and no significant 
improvements were noted after NR supplementation (Figure 3-7). Measurements included left 
ventricle thickness (LVPWd) (FXN KO –NR 0.85 ±02.3 vs FXN KO +NR 0.78 ±0.12 mm, 
p=0.53), ejection fraction (FXN KO –NR = 26.6 ±9.7 vs. FXN KO +NR 30.6 ±13.5%, p=0.53), 
fractional shortening (FXN KO –NR 12.4 ±4.7 vs. FXN KO +NR 14.5 ±6.7 %, p=0.51) and rates 
of contraction (FXN KO –NR 5165 ±1019 vs FXN KO +NR 4683 ±760 mmHg/sec, p=0.42) and 
relaxation (FXN KO –NR -4099 ±1022 vs. FXN KO +NR -3613 ±807 mmHg/sec, p=0.42). 
Diffuse cardiac fibrosis was evident in FXN KO hearts at 10 weeks and there was no significant 
difference in fibrotic infiltration of the heart after NR therapy (Figure 3-7). 
 
 
 
Figure 3-6. Mitochondrial protein acetylation increases in response to NR treatment in FXN KO 
mice. (a) Oral NR therapy is effective at significantly augmenting NAD+ content in FXN KO mice. (b) 
Mitochondrial protein lysine acetylation increases in NR-treated FXN KO hearts.  
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TAT-FXN protein replacement therapy in FXN/SIRT3 DKO mice is sufficient to decrease, but 
not normalize, mitochondrial protein acetylation  
   
 We next asked whether replacement of FXN in the FXN/SIRT3 DKO mouse would be 
sufficient to rescue cardiac function. We have previously published data that fusion of FXN to a 
cell-penetrant peptide, transactivator of transcription (TAT), or TAT-FXN, is capable of replacing  
 
   
Figure 3-7. No improvement in functional heart outcome in FXN KO mice after treatment with 
NR. (a) Comparison of functional cardiac parameters after NR therapy. (b) Representative images from 
cardiac tissue of FXN KO animals treated with NR demonstrate abnormal mitochondrial morphology, 
intraventricular fibrosis, and cardiac steatosis (images top to botto).  EF = ejection fraction; FS = 
fractional shortening; LVIDd = left ventricular internal diameter, diastole; LVPWd = left ventricular 
posterior wall diameter, diastole; EDP = end diastolic pressure; +dP/dt = rate of contraction; -dP/dt = 
rate of relaxation; Tau (weiss) = time constant of ventricular relaxation; n=5-7/group; *=p<0.05.  	
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active FXN in FRDA cells and that TAT-FXN protein replacement therapy is effective at 
rescuing a severe phenotypic murine model of FRDA (98). We treated FXN/SIRT3 DKO mice 
(n=4) with twice weekly doses of TAT-FXN at 10 mg/kg body weight via intraperitoneal 
injection from 2 weeks of age to 10 weeks of age. At the end of therapy, we harvested heart tissue 
for further analysis to compare to untreated FXN/SIRT3 DKO mice.  
 We found that TAT-FXN therapy was sufficient to reduce mitochondrial protein 
acetylation levels in the FXN/SIRT3 DKO hearts (Figure 3-8). This finding suggests that even in  
the absence of SIRT3, the presence of functional FXN alone is sufficient to reduce the burden of 
Figure 3-8. FXN replacement in FXN/SIRT3 DKO mice reduces cardiac mitochondrial protein 
lysine acetylation. (a) FXN expression increases after TAT-FXN therapy. (b) Global cardiac whole cell 
and (c) mitochondrial lysine acetylation decreases in FXN/SIRT3 DKO hearts after treatment with TAT-
FXN. (d) FXN/SIRT3 DKO mice treated with TAT-FXN exhibit persistent mitochondrial ultrastructure 
defects, fibrosis and cardiac steatosis  (images left to right).  	
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abnormally high levels of protein acetylation, possibly by allowing acetyl CoA intermediates to 
enter the TCA cycle via restoration of aconitase activity (98).  
 Despite therapy with TAT-FXN, immunohistochemical analysis and electron microscopy 
revealed cardiac fibrosis and steatosis, and widespread abnormalities in mitochondrial 
ultrastructure, similar to untreated animals. These results demonstrate that SIRT3 activity is 
necessary to fully rescue cardiac function in the FXN/SIRT3 DKO mouse model, and provides 
further evidence that SIRT3 plays an important role in FRDA cardiomyopathy. For instance, 
findings of myocardial lipid accumulation even after FXN replacement in the double knockout 
heart is not unsurprising considering others’ reports that absence of SIRT3 leads to dysfunctional 
lipid metabolism. Inactive SIRT3 may, in fact, be a major contributor to disordered lipid 
metabolism in the FXN KO heart due to its inability to deacetylate and activate fatty acid 
enzymes. 
 
 
Discussion  
 
 This study provides the first report that the conditional loss of SIRT3 expression in the 
heart of a model of known mitochondrial heart disease is sufficient to cause a robust increase in 
cardiac mitochondrial protein acetylation and worsen heart function. Removing expression of 
SIRT3 in the FXN KO heart dramatically increases protein acetylation and worsens the functional 
outcome of end-stage heart failure. Loss of SIRT3 in the FXN KO heart also exacerbates 
underlying cellular features of maladaptive ventricular remodeling, such as increased fibrosis of 
ventricular walls. Perhaps even more importantly, site-specific deletion of SIRT3 in our model 
leads to poorer physiologic outcomes, such as accelerated heart failure-associated wasting and 
increased mortality rate in response to surgical stress.  
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 FXN has an established role in manufacturing of Fe-S cluster subunits needed for 
enzymes vital to oxidative metabolism. The FXN KO model thereby acts as a “stressed heart” 
model in which to study the influence of SIRT3 on the pathologic process of heart failure. SIRT3 
activity is impaired in FRDA hearts likely due to the decreased bioavailability of NAD+ and to 
oxidative damage to SIRT3 (9). Other cardiac diseases with abnormal metabolism and energy 
homeostasis are expected to result in impaired SIRT3 activity in a similar manner, resulting in 
abnormal mitochondrial protein acetylation in the heart and impaired cardiac function. Such heart 
disease candidates include inherited mitochondrial cardiomyopathies, diabetic and metabolic 
syndrome heart disease, acquired cardiac hypertrophy, age-related and ischemic heart disease, 
and heart failure (42, 71, 104, 105). For example, the ischemic heart results in a shift in redox 
state with accumulation of NADH (87), mirroring the consequential disturbance in energy 
equivalents in the FRDA heart.  
 Recent work has shown that exogenous treatment with NAD+ precursors can increase 
NAD+ levels in mitochondria, reduce protein acetylation, and activate sirtuins (58-61). We were 
surprised to observe that treating FXN KO mice with NR increased mitochondrial protein 
acetylation despite an increase in mitochondrial SIRT3 expression levels. NR-treatment may act 
to increase acetyl CoA levels by upregulated processing of acetate, pyruvate, and fatty acids via 
increased SIRT3 deacetylation of pyruvate dehydrogenase (PDH), acetyl coA synthase 2 
(AceCS2), and the fatty acid oxidation enzymes (e.g. LCAD). This acetyl CoA would then be 
blocked at the TCA cycle due to reduced aconitase secondary to absence of FXN. Increased 
acetyl CoA would then favor acetylation via non-enzymatic acetylation of protein lysine residues 
(106).  
 Mitochondrial-targeted protein replacement therapy with TAT-FXN is effective at 
rescuing a murine model of FRDA with multiple tissue involvement (98). We were able to reduce 
mitochondrial protein acetylation in the FXN/SIRT3 DKO mice with TAT-FXN replacement 
therapy. This provides evidence that presence of SIRT3 deacetylase activity in the mitochondria 
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is not necessary to modulate acetylation levels. Most likely, acetylation went down in the 
presence of FXN because of a reduction in the burden of excess acetyl CoA that was able to enter 
the TCA cycle from increased aconitase activity (98). This finding that modulation of acetylation 
is not dependent on SIRT3 activity is of interest and applicable to other animal models of 
mitochondrial or metabolic heart disease and warrants further investigation. 
 Despite a modest reduction in mitochondrial protein acetylation, TAT-FXN therapy was 
not successful at alleviating heart failure, left ventricular remodeling or cardiac steatosis in the 
double knockout mice. This suggests that SIRT3 function is necessary to normalize cardiac 
function. For instance, ventricular tissue of FXN/SIRT3 DKO demonstrates myocardial lipid 
accumulation, which is not alleviated with TAT-FXN replacement therapy. This finding is not 
unsurprising considering others’ findings that absence of SIRT3 leads to dysfunctional lipid 
metabolism. These results imply that inactive SIRT3 in the FXN KO heart may be the main 
contributor of dysfunctional lipid metabolism, due to its inability to deacetylate and activate 
targeted fatty acid oxidation enzymes, such as LCAD (42). However, because of our previous 
documentation that acetylation is negatively correlated with heart function, it would be of interest 
to determine if there is a dose-dependent response of acetylation and cellular and physiologic 
outcome to TAT-FXN replacement therapy. This could be achieved by pursuing trials of larger or 
more frequent doses of TAT-FXN in the double knockout mouse.  
 In conclusion, we demonstrate that loss of SIRT3 in the FXN KO heart leads to worse 
heart function and SIRT3 activity is necessary to rescue heart function in a murine model of 
FRDA cardiomyopathy. These results suggest that SIRT3 contributes to the pathophysiology of 
FRDA heart disease and may represent a therapeutic target to improve cardiac metabolism and 
physiologic function and prevent unremitting progressive heart disease.  
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Methods 
 
Mouse breeding and genotyping. This study was approved by the Institutional Animal Care and 
Use Committee of Indiana University. We used site-specific Cre-lox recombination to carry out 
gene deletions of interest. We used FXNfl/fl mice to create FXN KO mice that were homozygous 
for heart and skeletal muscle deletion of FXN (MCK-Cre: FXN KO), as previously published 
(55). We used SIRT3fl/fl mice to create SIRT3 KO mice that were homozygous for heart and 
skeletal muscle deletion of SIRT3 (MCK-Cre: SIRT3 KO) as described by others (107). The 
double knockout, or FXN/SIRT3 DKO, mice were homozygous for both SIRT3 and FXN 
expression loss restricted to heart and skeletal muscle (MCK-Cre: FXN KO/SIRT3 KO). Data 
was collected at 10 weeks of age (±5 days). Controls were age- and sex-matched healthy 
littermates (FXNfl/fl or SIRT3fl/fl, as indicated in text).  
 
Lifespan, weight collection and mortality rate. Mice of each genotype were weighed twice 
weekly and natural death date recorded. Surgical stress-related mortality was determined by 
occurrence of spontaneous death in <10 minutes from right paratracheal skin incision under 
controlled anesthesia, and survival determined by survival of ≥10 minutes under equivalent 
conditions. 
 
Echocardiography (ECHO). Mice were anesthetized with isoflurane and placed on a warming mat 
with continuous monitoring. Transthoracic ECHO images were obtained using a VisualSonics® 
2100 ultrasound machine for small animal imaging and MS400 transducer (Fujifilm 
VisualSonics, Inc., Toronto, Canada). Functional parameters of the left ventricle and outflow 
tracts were measured using standard assessment techniques (108). Relative wall thickness (RWT) 
was calculated by (2*LVPWd)/LVIDd (109). 
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Cardiac Catheterization. Mice were anesthetized with isoflurane and placed on a warming mat 
with continuous monitoring. Pressure-volume loops were obtained directly using a 1.2 F 
microconductance catheter (Scisense, Transonic Systems Inc.), which was inserted into the right 
carotid artery through a small neck incision and advanced retrograde into the left ventricle. The 
ADVantage pressure volume system (Scisense, Transonic Systems Inc.) was used to acquire 
pressure, admittance, phase shift, and amplitude, and real time pressure-volume data was 
displayed and analyzed offline using specialized software (Labscribe 2, iWorx, Dover, NH).   
 
Nicotinamide riboside therapy. FXN KO mice and healthy controls (n=6) were treated with oral 
gavage administration of nicotinamide riboside chloride (Niagen, ChromaDex, Inc.) at 500 
mg/kg/day from 4 weeks of age until sacrifice at 10 weeks of age. Analysis with ECHO and 
catheterization as described above. Hearts were harvested the completion of study and 
subsequently processed or flash frozen for later analysis. Results were compared to untreated age- 
and sex-matched animals. NAD+ levels were measured using colorimetric detection of NAD+ 
concentration based on a standard curve and expressed as pmol/µg of protein (NAD+/NADH 
Assay Kit, Abcam ab65348).  
 
TAT-FXN targeted protein replacement therapy. TAT-FXN was generated as previously 
published (98). FXN/SIRT3 DKO mice were dosed 2 days/week at 10mg/kg body weight via 
intraperitoneal route and compared to untreated age-matched FXN/SIRT3 DKO animals. FXN 
levels in heart tissue of treated animals were determined by ELISA within 4 hours of last drug 
dose (Human Frataxin ELISA Kit, Abcam ab176112).  
 
Histology. Ventricular tissue selected for histology was fixed in 10% formalin and paraffin 
embedded. Histological analysis included hematoxylin and eosin (H&E) and Masson’s trichrome 
to detect collagen as a measure of fibrosis. Collagen quantification was performed using ImageJ 
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(IJ1.46) (110) to measure percent area of tissue positively stained for collagen. Three to five 20x 
digital micrographs were obtained from each tissue section that underwent quantification studies.  
 
Electron Microscopy (EM). Ventricular tissue selected for electron microscopy was fixed in 2.5% 
glutaraldehyde and underwent sectioning and uranyl acetate staining by the Electron Microscopy 
Center of Indiana University School of Medicine. Three separate sections from each animal strain 
were selected for quantification analysis. Quantification methods were similar to methods used in 
(111, 112) and our previous work (98). Abnormal mitochondria were identified as those 
containing electron-dense inclusions, cristae loss or dissolution, and/or collapsed or condensed 
cristae. Mitochondria and myofibril area was measured using ImageJ (IJ1.46).  
  
Isolation of Cardiac Mitochondria. Mitochondrial isolation followed the method described in our 
previous work (9). Freshly harvested hearts were submerged in ice-cold mitochondrial isolation 
buffer (mannitol 220 mM, sucrose 70 mM, MOPS 5 mM, EGTA 2 mM, pH 7.0). Heart tissue was 
weighed, homogenized with Dounce tissue grinder, and then subjected to differential 
centrifugation. The cytosolic portion was reserved separately and the final mitochondrial pellet 
was resuspended in RIPA buffer and used immediately for western blotting or flash frozen for 
later analysis.  
 
Antibodies and Western Blotting. Primary antibodies included anti-acetyl-lysine (Cell Signaling 
#9441), anti-SIRT3 (Cell Signaling #5490), anti-SOD2 (acetyl K68) (Abcam ab137037), anti-
SOD2 (Cell Signaling #13141), anti-VDAC (Cell Signaling #4866), anti-GAPDH (Cell Signaling 
#5174), anti-FXN (generous gift of Grazia Isaya, Mayo Clinic, Rochester MN), and to the 
electron transport chain complexes: anti-CI-NDUFA9 (Abcam ab14713), anti-CII-SDHB (Abcam 
ab14714) and anti-CIII-UQCRFS1 (Abcam ab14746). Band intensity was measured using ImageJ 
(IJ1.46) and analyzed with established methods (110, 113, 114).     
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Statistics.  All calculations, analyses and graphs were performed using SigmaPlot (Systat 
Software, Inc.). Two groups were compared using a two-tailed student’s t test for samples with 
equal variance. Three or more groups were compared using ANOVA and followed by the Holm-
Sidak approach for multiple comparisons. Final data are presented as mean (±SD). Alpha was set 
at 0.05 and power at 0.800. A p-value of <0.05 was considered statistically significant.  
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CHAPTER 4   
 
CONCLUSION 
 
Heart disease exerts significant patient morbidity, mortality and cost burden to health 
care infrastructure in the United States (1). Heart failure, in particular, contributes much to this 
burden and little can be offered by way of treatment for this widely prevalent and etiologically 
diverse condition (2). Therefore, it is of utmost importance to illuminate common underlying 
mechanisms causing the cardiac dysfunction that leads to development of heart failure in order to 
develop effective therapies. Metabolic disturbance is one such common feature in cardiovascular 
disease, such as that which occurs in ischemia, diabetic cardiomyopathy, hypertrophy and heart 
failure, and has garnered relevant attention by researchers in recent years (115-118).  
As cellular powerhouses, mitochondria serve as a site where the pathways of metabolism 
converge to generate vital energy needs for cell function. The heart, in particular, relies heavily 
on consistent energy generating capacity of the mitochondria. Mounting evidence suggests that 
mitochondrial dysfunction underlies the metabolic disruption that accompanies cardiovascular 
decline, underscoring the importance of mitochondrial failure as a pathogenic mechanism for 
heart disease progression (3, 4). For this reason, mitochondria have become a major focus in the 
investigation of cardiac disease in recent years and are poised to become a target of therapeutic 
intervention potentially for a vast spectrum of cardiac diseases.  
Protein acetylation has gained recognition in recent years as an important post-
translational processing mechanism to regulate cellular metabolism in response to shifting energy 
needs. The vast majority of mitochondria protein acetylation appears to be orchestrated by the 
NAD+-dependent deacetylase, SIRT3, which has the capacity to read and regulate the energy 
needs of the cell (119). It is not surprising that loss of SIRT3 activity leads to significant 
downstream consequences as the capacity of mitochondria to meet the cell’s metabolic demands 
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fails in the absence of acetylation regulation (25, 39, 42, 59). Abnormally high levels of 
acetylation are observed in a range of cardiac diseases. For instance, human heart tissues from 
patients in heart failure demonstrate hyper-acetylation, as do mouse models of diabetic and 
mitochondrial cardiomyopathy (9, 104, 120, 121). This serves to illustrate that abnormal 
acetylation is occurring in diseased myocardium arising from distinct etiologies and is a shared 
pathologic feature amongst cardiovascular diseases.  
A promising characteristic of SIRT3 is that its activity is modifiable via exogenous 
supplementation with NAD+ precursors, nicotinamide riboside (NR) or nicotinamide 
mononucleotide (NMN). SIRT3, which requires NAD+ as a cofactor, responds to a boost in 
mitochondrial NAD+ content with increased deacetylase activity. This, in turn, leads to decreased 
acetylation levels, improved mitochondrial function and resultant cardioprotection (59, 60, 121). 
Taken together, mitochondrial protein lysine acetylation could serve as a modifiable target for 
therapies aimed to regulate cardiac metabolism in an attempt to alleviate the burden of heart 
disease.   
The congenitally acquired condition of FRDA is a relentlessly progressive and fatal 
mitochondrial disease in which the majority of premature death occurs due to cardiac causes. 
Patients with FRDA develop hypertrophic cardiomyopathy leading to heart failure, culminating 
with death in the third or fourth decade of life. There is no effective cure. The FXN-deficient 
mitochondria have robust levels of acetylated proteins. This is likely due to inherently low levels 
of NAD+ despite cellular energy deprivation, and high levels of acetyl CoA due to decreased 
activity of aconitase. Based on what we know of mitochondrial protein acetylation and the central 
role of SIRT3 in providing cardiac protection, I hypothesized that hyperacetylation of FXN 
deficient mitochondria leads to worsening of the mitochondrial function, and that this, then, 
translates to a decline in left ventricular dysfunction. The impact of hyper-acetylation on the 
outcome of FRDA heart disease had not been previously explored. The overarching purpose of 
my project was to investigate the relationship between acetylation and left ventricular function in 
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FRDA heart disease in order to determine whether deregulation of acetylation in the FRDA heart 
leads to worse cardiac outcome.  
In Chapter 2, I used an established murine mouse model of FRDA heart disease (FXN 
KO) to follow the progression of heart dysfunction and the pattern of lysine acetylation as it 
proceeded through early- mid- and late-stage heart disease. I was able to document that FXN KO 
murine hearts mimic FRDA heart disease with onset of early diastolic dysfunction and 
hypertrophic cardiomyopathy progressing rapidly to decompensated, dilated systolic and diastolic 
heart failure. I also documented that mitochondrial protein acetylation in these hearts is 
progressive and tracts that of progressive cardiomyopathy. Most importantly, heart function and 
acetylation is connected by a strong negative correlation in the FXN KO heart. Findings in 
chapter 2 lead to the conclusion that abnormal acetylation contributes to the pathophysiology of 
heart disease in FRDA.  
Further insights were gained into the link between metabolic disruption and the 
pathological process of cardiomyopathy due to FXN loss. First, there were findings of lipid 
metabolism dysfunction, evidenced by marked accumulation of lipids in the cardiomyocytes. This 
is likely related, at least in part, to increased acetylation of LCAD secondary to decreased activity 
of SIRT3. Interestingly, conditional loss of FXN leads to an inability to maintain normal 
thermogenesis in the face of a prolonged hypothermic insult. This finding is similar to that of 
murine models with loss MCAD or VLCAD, and thus suggests that cold intolerance is a product 
of the inability to properly metabolize lipids in the FXN KO heart. Second, measurable 
mitochondrial respiratory function is diminished in these hearts. This observation is not surprising 
based on the insult to Fe-S containing respiratory enzyme machinery resulting from loss of FXN, 
but may also be contributed to by loss of SIRT3 and its ability to modulate the activity of the 
electron transport chain via deacetylation of complex I. Further studies would be needed in order 
to determine the contribution of SIRT3 dysfunction in mitochondrial respiratory capacity. This 
could be accomplished by comparing mitochondrial respiratory rates in FXN KO and 
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FXN/SIRT3 DKO to determine whether a difference exists. 
Because of the strong negative correlation between acetylation and cardiac function in 
FXN KO heart, I hypothesized that modifying acetylation levels would lead to changes in heart 
function. In Chapter 3, we generated a “double knockout” mouse with ablation of both FXN and 
SIRT3 in the heart (FXN/SIRT3 DKO) and I compared acetylation and heart function to the FXN 
KO mouse model. The mitochondrial acetylation of the FXN/SIRT3 DKO heart was markedly 
increased compared to age-matched FXN KO hearts. As expected, global measures of cardiac 
function and left ventricular remodeling in the FXN/SIRT3 DKO mouse were significantly worse 
compared to the FXN KO. Further, the FXN/SIRT3 DKO mice suffered significantly higher 
mortality rates in response to procedural stress and exhibited an accelerated rate of weight loss 
coincident with onset of cardiac decline, compared to FXN KO mice. Taken together, these 
findings lead to the conclusion that loss of SIRT3 in the FXN KO heart leads to worse heart 
function, in conjunction with increased mitochondrial protein acetylation.  
I next asked whether reducing acetylation in the FXN KO heart would result in 
cardioprotection and attenuate previously observed cardiac pathology. I used exogenous therapy 
of the NAD+ precursor, nicotinamide riboside (NR) in order to stimulate SIRT3 deacetylase 
activity by providing enhanced cofactor bioavailability with the objective to reduce acetylation. I 
was surprised to discover that NR therapy lead to a modest increase in mitochondrial protein 
acetylation in the FXN KO hearts. This was despite its effectiveness at both 1) increasing NAD+ 
content and, 2) increasing mitochondrial SIRT3 expression. It is likely that increased SIRT3 
deacetylation activity lead to increased acetyl CoA via its substrates pyruvate dehydrogenase 
(PDH), acetyl CoA synthase 2 (AceCS2), and the fatty acid oxidation enzymes (e.g. LCAD). The 
excess acetyl CoA would then be blocked from processing in the TCA cycle due to reduced 
aconitase secondary to absence of FXN. Acetyl CoA intermediates independently attach to lysine 
residues in the mitochondria. Such an increase in acetyl CoA, as suspected in this case, would 
push the balance in favor of acetylation. Further studies comparing measurements of acetyl CoA 
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in the NR-treated and untreated FXN KO hearts would be the next step in pursuing the 
mechanisms underlying these biochemical results. The modest increase in acetylation was 
accompanied by no change in heart function. These findings lead to the conclusion that SIRT3 
activity alone is not sufficient to rescue heart function in the FXN KO in the face of increased 
levels of acetylation.  
Because of the contrast in acetylation state between FXN KO and FXN/SIRT3 DKO 
mitochondria, I expected that replacing FXN expression in the FXN/SIRT3 DKO would lead to 
reduced acetylation. And, indeed, increasing FXN expression using a protein replacement therapy 
(TAT-FXN) in the FXN/SIRT3 DKO mouse lead to a modest reduction in mitochondrial protein 
acetylation. This provides evidence that while acetylation is regulated by SIRT3 in the FXN KO 
heart, it is not solely responsible for acetylation, and agrees with the findings above.  
I then asked whether reducing acetylation in the FXN/SIRT3 DKO mice would improve 
cardiac pathology even in the absence of SIRT3. My objective was to begin to determine the 
contribution to left ventricular dysfunction in the FXN/SIRT3 DKO mouse attributable to SIRT3. 
Cardiac pathology in the TAT-FXN treated FXN/SIRT3 DKO mice was not improved compared 
to untreated animals. Taken together, these findings demonstrate that FXN expression is 
sufficient to modify acetylation and suggest that SIRT3 activity is necessary – but not sufficient – 
to improve heart function at a cellular and functional level in FXN-deficient hearts. 
However, because TAT-FXN therapy in the study mice did not effectively result in 
reducing acetylation to SIRT3 KO levels, as would be expected in response to normalizing FXN 
expression levels, this leads me to speculate whether there is a dose-dependent response of 
acetylation to TAT-FXN therapy. Further studies trialing higher concentrations, more frequent 
and earlier dosing schedules would be of great interest to pursue. It would also be of interest to 
determine whether there is a certain level of mitochondrial protein acetylation that is able to elicit 
the most response in cardiac outcome. This could be achieved by titrating acetylation 
modification in FXN/SIRT3 DKO hearts and measuring impact on cardiac outcome.  
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Together, these findings provide novel insight into the molecular and physiologic basis 
underlying the mitochondrial cardiomyopathy of FRDA. These results suggest that both SIRT3 
and acetylation play a contributory role leading to heart failure in FRDA. More studies are 
necessary in order to delineate the independent roles held by acetylation and SIRT3 and whether 
minimizing mitochondrial protein acetylation could mitigate left heart dysfunction in FRDA 
cardiomyopathy. Acetylation remains a promising therapeutic target in this childhood heart 
disease.  
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Appendix A  
 
 
List of Definitions  
 
+dP/dt = rate of pressure change in the ventricle   
 
Respiratory control ratio (RCR) = indicates the tightness of the coupling between respiration and 
phosphorylation; the ratio of respiratory state 3 rate (ADP-stimulated respiration): state 4 rate 
(oxygen consumption in the absence of ADP or any metabolic poisons or inhibitors) 
 
Tau (Mirsky) = time required for left ventricle pressure to fall to one-half of its value at end 
systolic pressure  
 
Tau (Weiss) = regression of log*pressure 
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Appendix B  
 
List of equations  
 
 
 
-dP/dt = -∆intra-ventricular pressure/∆time 
 
 
+dP/dt = +∆intra-ventricular pressure/∆time 
 
 
Rate of weight loss = median rate (∆mass (gm)/∆time (weeks)  
 
 
RWT = 2*LVPWd/LVIDd 
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